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Abstract
Biomathematics is a branch of science that aims at describing biological pro-
cesses in mathematical terms to frame and solve otherwise unsolvable research
questions in the biological and medical field.
Cardiovascular diseases are the number one cause of death in the world.
Metabolic diseases as metabolic syndrome and diabetes increase the risk of
cardiovascular diseases, due to disrupted lipid metabolism. Apolipoproteins
(apo) are particles attached to the lipid-carrying proteins (lipoproteins) and
give them properties. ApoC-III inhibits lipoprotein lipase, therefore lowering
down the release of the triglyceride from the lipoproteins to the tissues, apoE
is a ligand involved in the uptake of lipoproteins from the liver and apoA4
influences insulin secretion. Studying how fast the apolipoproteins are formed
and released in the blood (secretion rate (SR)) and how fast they are removed
from the blood (fractional catabolic rate (FCR)) enriches our knowledge on lipid
metabolism.
Apolipoprotein kinetics studies are only possible thanks to mathematical mod-
elling. So far the three apolipoproteins had not being measured in the same
study. We analyse the time series data generated from three experiments with
the nonlinear mixed effects modelling framework. The novelty consists in hav-
ing validated a structural model for all the apolipoproteins across three studies
and having chosen statistical error model. A covariance-variance matrix for the
random effects has been designed and it has been validated in 16 out of the 18
total occasions (three apolipoproteins with 2 occasions for 3 experiments).
Applications of the mathematical framework to the kinetic studies has led to
advancements in the realm of lipid metabolism.
In Paper I and II apoC-III kinetics is studied before and after hypercaloric fruc-
tose treatment in abdominally-obese individuals. In Paper I the modelling
framework developed in this thesis is presented and further applied to apoA4
and apoE kinetics; a strong bond has been uncovered between triglyceride
levels and the SR and PS of apoC-III and an association has been found be-
tween apoC-III and apoE kinetic parameters. In Paper II the results for apoC-III
are combined with lipoprotein kinetics analysis. Hypercaloric fructose intake
leads to an increase in triglyceride levels, but the mechanism behind this phe-
nomenon was so far unknown; in this work, results support the hypothesis
that the increase in apoC-III SR causes a rise in the apoC-III concentration with
subsequent increase in triglyceride level. In Paper III apoC-III and apoE kinetics
are analysed before and after a PSK9-inhibitor-based drug treatment in type-II-
diabetic individuals. ApoE FCR increases consistently and apoE diminishes as
a result of the treatment. Different elements suggest that the increase in apoE
FCR might be related to an increase in VLDL2 FCR.
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1 Background
Already in the 1623 Galileo was suggesting that the universe is written in math-
ematical language [1]. Mathematics can be used as a descriptive language
of aspects of reality and more specifically of some biological processes. Here
we use it to describe and analyse apolipoprotein kinetics. In Section 1.1 we
introduce differential equations and nonlinear mixed effect models, the main
mathematical tools used throughout the thesis. Before diving into the details of
the analysis, let us briefly introduce the motivation behind this applications.
Cardiovascular diseases (CVD) are the biggest cause of death in the world [2].
Abdominal obesity and Type II Diabetes are two risk factors for CVD [3, 4].
Dyslipidemia (abnormal composition of blood lipid profile) is one of the links
between type 2 diabetes and increased risk of CVD [5], while it represents an
aggravating factor for CVD in obesity [6]. Therefore lipid metabolism is a target
of research in metabolic diseases, and our focus within this domain will be on
apolipoproteins.
Apolipoproteins are proteins that are attached to the lipid carrying particles and
that give them different properties affecting their metabolism. Apolipoprotein
A4, C-III and E, the proteins that will be studied throughout the thesis, are
important for lipid metabolism, however much of our results may be applied
to other proteins as well. In order to highlight their role, let us first intro-
duce in Section 1.2 lipid metabolism and lipoproteins and let our main players,
apolipoproteins, enter the field.
The scope of the experimental and mathematical framework depicted in this
thesis is much broader than the answer to the very specific questions answered
in the thesis. In Section 1.3 the horizon of vitally important questions that can
be answered in this framework will be laid out, after presenting more in detail
the extent of the type II diabetes and obesity pandemic. A few of the past
discoveries obtained through this framework will be also presented, with the
goal of highlighting the complexity of the study of the metabolic disease and
the role played by apolipoproteins.
Mathematical biology makes fruit of the advances in mathematics and statistics
to further the knowledge on biological systems. Here it is used to investigate
the kinetics of apolipoproteins. We will illustrate the interdependency between
the experimental setup and the mathematical description in Section 1.4.
1
2 1. Background
1.1 Mathematical foundation
The awe-inspiring sight of nature has been stimulating the creation of math-
ematical tools with a descriptive purpose since a long time ago. Pythagoras,
Fibonacci and Leonardo da Vinci are all examples thereof. The objects created
in this meditative state have shown a wider applicability than the description
of the specific aspect of reality, from which they sprang. The generality of the
mathematical language represents its power.
Mathematics does not only have a descriptive purpose, but it can help access
otherwise unknown aspects of reality and in some cases predict the future.
This thesis is one among plentiful examples of how mathematics can be used
for solving an otherwise unsolvable problem and opening the doors to a deeper
understanding of reality. Let us therefore introduce the main mathematical
object in our thesis, a parametric system of differential equations.
1.1.1 Differential equations
Let x represent a variable dependent on time t. A differential equation pro-
vides a description of the interrelationship among the change in the dependent
variable x in time (its derivative), x and the independent variable, time. The
differential equation is usually accompanied by an initial condition.
g
(
t, x,
dx
dt
, ...,
d(n−1)x
dt(n−1)
,
dnx
dtn
)
= 0 (1.1)
x (t0) = x0 (1.2)
where d
nx
dtn represents the n-th order derivative. Solving a differential equation
means finding x(t) that satisfies equations 1.1 and 1.2. The equation 1.1 is
implicit, since the dependency of the derivatives on the variables of the system
is not clear. If the equation only contemplates the first derivative of x and
no other derivatives of higher order, the equation is of first order (d = 1).
An explicit differential equation shows the dependency of the highest order
derivative on the independent variable, on the dependent variable and on its
derivatives of lower order. Here we will focus on explicit differential equations
of first order.
dx (t)
dt
= f (x(t), t) (1.3)
x (t0) = x0 (1.4)
Such a mathematical description as in equations 1.3 and 1.4 can be used when
the dynamics of the system is already clear.
A parametric equation is a family of equations which can be described with a
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unified mathematical formula. Different values for the parameters will specify
a different equation. The parametrization of an equation is suitable when we
know the behaviour of x on a qualitative level, but we ignore the quantitative
aspects of the system.
One dependent variable x is not enough to describe the kinetics of apolipopro-
teins, therefore we will use instead a vector of variables, denoted by x and we
will use a system of differential equations instead of a single equation. A para-
metric system of first-order explicit differential equations is the tool that will be
used throughout the thesis to describe the kinetics of the apolipoproteins.
dx (t)
dt
= f (x(t), t,k) (1.5)
x (t0) = x0 (k) (1.6)
1.1.2 Nonlinear Mixed Effects models
Fixed and mixed effects Many studies are interested in analysing the impact
of different factors on an outcome variable. For example in a quality control
analysis, the weight of a box of syringes could be measured by different scales.
In this case the factors are the boxes and the scales. The effect of each single
factor on the outcome could be of one of the two types:
• fixed, if we assume that the levels of the factors within the study exhaust
the whole extent of the total level for that factor
• random, if we assume that the levels of the factors observed in the study
are only a sample from a distribution and do not exhaust all the possible
levels of the study .
Most likely the choice of an effect as random gives rise also to a fixed effect. For
example if we choose the individual to be a random effect, then the total popu-
lation, of which the individuals in the study are just a sample, will represent
the fixed effect. Whether a factor is fixed or random depends on the purpose of
the study. For example, if the same individual is measured in different days,
each day could be seen as contributing in a specific and unique way to that
specific measurement (fixed effect). On the other hand, we expect that the
variation within each day is due to a measurement error and we might want
to assume that this has a normal distribution centred in 0, since we expect the
measurement error to be positive at times and negative at times. In this case the
specific days would be a random effect.
A model has mixed effects when it presents a combination of fixed and mixed
effects. The fixed effects will appear in the model equations as fixed parameters,
while the random effects will translate into random parameters for the model.
In our model throughout the thesis the factors and their effects are:
• individual –> random
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• population –> fixed
Linear and nonlinear models A model is linear when the partial derivatives
with respect to each parameter of the model is independent on the other param-
eters of the model. It is nonlinear if this derivative is dependent on at least one
of the other parameters of the model or if it does not exist or it is discontinuous
[7].
Birth and development of NLMEM The expression nonlinear mixed effects
models denominate nonlinear models that have mixed effects (both fixed and
random).
While models with merely fixed effects can benefit from the least squares esti-
mation, introducing random effects adds a level of complexity, since parameter
distributions shall be introduced. Therefore more sophisticated mathematical
instruments are needed.
The first application of ANOVA, method for the analysis of variance, to quantify
the contribution of different factors in linear mixed effects models, appeared in
1921 in Fisher [8]. The standard two stage method (STS) used to be applied to
draw information on the population behaviour from the individual estimates,
obtained through the least square minimization. This was a first attempt to
draw conclusions on the population kinetics based on data from a sample of
individuals. Only in 1977 a parameter estimation method was introduced for
NLMEM [9] and applied to pharmacokinetics that would encompass the de-
scription of the parameter as random and information on the distributions. The
study of the absorption, diffusion and elimination of a drug is still one of the
main application fields of NLMEM.
In the last decade of the 20th century, Lindstrom and Bates ([10]), Wolfinger
([11]) and Pinheiro and Bates ([12]) contributed in developing and clarifying the
different methods available for the implementation of NLMEM. The NLMEM
parameter estimation makes use of a maximum likelihood approach. At the very
end of the 20th century, a stochastic version of the expectation-maximization
(EM) algorithm was proven to converge [13]; this algorithm (stochastic approxi-
mation of EM, denoted as SAEM) is now the basis of the parameter estimation
in Monolix, the software used in this work. One recent advance in the NLMEM
parameter estimation was the introduction of sensitivity equations to have
a more exact gradient estimation [14]. This method was also generalized to
NLMEM with stochastic dynamics [15].
1.2 Lipid Metabolism
Lipids represent one of the sources of energy for our body, together with car-
bohydrates and proteins. Lipids are also important for cell membranes and
1.2. Lipid Metabolism 5
hormones.
Lipids are categorized by their structure and function. Fats or triglyceride are a
category of lipids. A triglyceride molecule is derived from glycerol and fatty
acids. Lipids can be used as an energy source by almost all the tissues. The
brain is an exception, in that it is fuelled by carbohydrates and ketone bodies,
produced by the liver.
The lipid fat storage is mainly found in adipose tissues and accounts in total for
more than 80 per cent of our energy reserves.
Lipid metabolism starts with the intake of fat-containing food, continues with
absorption and hydrolysis of fats in the intestine, secretion and circulation of
lipid particles in the blood stream. By releasing fatty acids to peripheral tissues,
these particles increase their density and eventually get cleared by liver cells.
Other lipid-carrying-particles are synthesized by the liver, they travel through
the blood stream and follow the same journey as the dietary lipids.
Since lipids are not water-soluble, they need a means to be transported in the
blood stream. Lipoproteins fulfil this role.
On the surface of lipoproteins there are various proteins, called apolipoproteins.
Lipid metabolism is a very wide topic. We choose to focus our attention on one
important piece of the puzzle, apolipoproteins kinetics, focusing our attention
on apolipoproteins A4, E and C-III.
1.2.1 Lipoproteins
Lipoproteins are spherical particles with a core of triglyceride and cholesterol
ester, and a surface monolayer of phospholipids. Lipoproteins do not only trans-
port lipids among different parts of the body. They also facilitate the removal of
toxins from infected areas.
There are mainly three categories of lipoproteins.
Chylomicrons are produced by the intestine and their core is represented by an
apo B-48 molecule. Chylomicron remnants result from a transfer of triglycerides
to the peripheral tissues.
The two remaining categories of lipoproteins are produced in the liver.
Apo B-100 carrying lipoproteins have apoB-100 molecule at their core. Their
role is to facilitate the transport of lipids from the liver to the tissues. When
losing triglycerides to the peripheral tissues through the action of lipoprotein
lipase (LPL), these apolipoproteins decrease their density, therefore we can
subdivide this category into further subcategories depending on their density.
These are: VLDL (very low density lipoproteins), which can be further subdi-
vided into VLDL1 and VLDL2, IDL (intermediate density lipoproteins) and
LDL (low density lipoproteins). The composition of the lipoproteins varies
among the different groups, with lower density pointing to an earlier stage of
the lipoprotein life cycle.
Chylomicrons remnants and apoB-100-carrying particles are removed from the
6 1. Background
circulation through LDL receptors or LPR (LDL receptor related protein).
The last category of lipoproteins is HDL (high density lipoproteins), that trans-
ports the cholesterol back to the liver. ApoAI is the apolipoprotein at their
core.
1.2.2 Apolipoproteins
ApoB-100, apoB-48 and apo-AI are respectively at the core of ApoB-100 carrying
particles, chylomicrons and HDL.
Additional apolipoproteins with diverse roles can be found in the lipoproteins.
Here we will focus on apoA4, apoC-III and apoE, object of our analysis.
ApoA4 Mainly produced in the intestine, apoA4 can be found on chylomi-
crons, in HDL and in a free form and embodies different roles. Here we report
several results about apoA4.
Men with coronary artery disease had significant lower apolipoprotein A4 level
than the control counterpart [16]. ApoC-II binds with LPL to allow triglyceride
release to the tissue. ApoA4 stimulates LPL activity, leading to an increased
removal of apoC-II containing particles [17]. This stimulating role is lost in
absence of apoC-II containing particles.
Apolipoprotein A4 plays a role in the inverse cholesterol transport [18] and
inhibits lipoprotein oxidation [19, 20, 21, 22]. Moreover apolipoprotein A4
stimulates insulin secretion, therefore playing an important role in glucose
homeostasis [23].
ApoC-III ApoC-III is part of the family of apolipoproteins C. These proteins
are mainly synthetized in the liver and can exchange among the lipid particles,
therefore they can be found in all the three categories of lipoproteins. ApoC-III
inhibits LPL and hepatic lipase. Not only does apoC-III influence the triglyc-
eride blood concentration by its action on LPL, but underlying links between
apoC-III and triglyceride are being unravelled also at a cellular level. A high
fat diet failed to stimulate VLDL1 production in apoC-III deficient mice, while
this strategy was successful in mice with reconstituted apoC-III expression [24].
Cell culture in lipid-rich environment confirmed the link between apoC-III and
VLDL1 secretion [25].
In individuals with abdominal obesity, VLDL1-triglyceride concentration corre-
lates with apoC-III plasma concentration, while it does not correlate with LPL
activity [26], highlighting once more the deep connection between apoC-III and
triglyceride.
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ApoE Apolipoprotein E is mainly synthetized in the liver and in the intestine.
ApoE facilitates the removal of lipoproteins by binding with the LDL-family
receptors and with LRP [27, 28]. Its role in the removal of lipoproteins is not
limited to this. In fact apoE is also a ligand for cell-surface heparan sulfate pro-
teoglycans (HSPGs) which, independently of LDL-family receptors, contributes
to the lipoprotein clearance [29].
1.3 Research domain
1.3.1 Obesity and diabetes epidemics
In 2016 the World Health Organization (WHO) reported that 650 million of
people, 18 years and older, were obese (13% of the global population in this age
range) and that all over the world, the incidence of obesity has almost tripled
since 1975 [30], while the number of people with diabetes in 2014 (422 millions)
has almost become four-fold the one in 1980 [31]. More than 280000 were the
average annual deaths attributable to obesity only in the United States in 1999
[32].
Abdominal obesity Obesity, as normally used in global statistics, indicates
when the body weight divided by the squared height (BMI) exceeds 30 kg/m2.
On the other side, abdominal obesity, measured mainly as waist-to-hip cir-
cumference ratio or waist circumference, is a stronger predictor than BMI for
incidence of cardiovascular diseases [33]. Abdominal obesity is one of the
characteristics of metabolic syndrome [34]. While subcutaneous abdominal fat
behaves similarly to the other adipose tissues, high level of visceral fat impairs
metabolic functioning [35], by upregulating the free fatty acid release from the
visceral fat and thereby fostering an accumulation of free fatty acids in other
tissues (cardiac, pancreatic, liver and more). This in turn perturbs the normal
functioning of these tissues.
Type II Diabetes Measures of abdominal obesity are strongly associated with
incidence of type II diabetes. Type II Diabetes is not the only form of diabetes.
This family of diseases entails insufficient production (Type I) or disfunctional
use of insulin (Type II), an hormone responsible for the blood glucose levels.
Type II Diabetes increases the risk of vascular diseases [36].
Consequences for lipid metabolism
Though not universally present in type II diabetic patients [37], dyslipidemia
(high fasting and postprandial triglyceride levels, high LDL levels and low
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HDL levels) represents the link between this disease and an increased risk of
cardiovascular event [5]. Another marker of worsened lipid profile is a high
ratio (bigger than 5) of total cholesterol over HDL cholesterol. Dyslipidemia, as
measured in this way, is associated to abdominal obesity, across different ethnic
groups [38]. Viscerally [39] and abdominally obese individuals [40] have higher
triglyceride levels than their normal counterpart.
1.3.2 Purposes of kinetic studies
The experimental and mathematical framework that will be introduced in Sec-
tion 1.4 and explained in depth in Chapter 3 can answer many questions. While
the model used in this thesis is specific to apolipoproteins, different models can
be used with the same framework to study lipoproteins. Therefore here we will
introduce the plethora of questions that can be answered with this framework,
with the goal of highlighting its importance in the study of metabolic diseases,
the associated dyslipidemia and drug efficacy.
As will be clear in Section 1.4, this framework allows us to study the kinetics of
lipoproteins and apolipoproteins, so their lifecycle, and not only their concen-
tration. That is, it is possible to study rates of production and clearance.
Three are the main purposes of kinetic studies and this will be discussed below.
An additional paragraph will summarize information on some ameliorative
treatments, whose effect can be better understood through the use of kinetic
studies.
Kinetics for the healthy individual Our end goal is to study disruptions in
apolipoprotein and lipoprotein kinetics in a disease state, but important in this
direction is also to study how the kinetics looks like in a normal state. This
allows us to define normal ranges of production and clearance.
Comparison with disease state Comparing the kinetics in normal individuals
with the disease state let us uncover differences in the kinetics and potentially
understand which mechanism is behind the disruption in lipid concentration
in the disease state. Beside highlighting disruptive pathways, this also may
suggest which pathway to target by treatments and interventions.
Treatment and drugs High fasting and postprandial triglyceride are a marker
of dyslipidemia, together with high LDL and low HDL. Several drugs and
lifestyle interventions aim at improving the lipid profile, and our interest is
in quantifying the effect on lipoproteins and apolipoproteins (since these are
involved in lipid metabolism). While measuring the concentration of a biologi-
cally interesting quantity, be it apolipoproteins and lipoproteins, highlights the
net effect of the treatment, kinetic studies can point out to whether the resulting
change in concentration is due to a change in the production or in clearance of
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the particles.
Alongside therapies to improve the lipid profile, other experiments are per-
formed in order to prove or disprove an hypothesized deleterious effect of a
treatment.
Whether the intervention aims at improving the lipid profile or at confirming a
potential negative effect of an agent, apolipoprotein and/or lipoprotein kinetics
studies combined with mathematical modelling helps us to draw conclusion on
its effects.
Ameliorative interventions Since dyslipidemia increases the risk for cardio-
vascular diseases, interventions to improve the lipoprotein profile are needed.
Though lifestyle interventions in terms of more physical exercise [41] and
changes in diet [42] have been proven to be successful in improving the lipid
profile, they do not always suffice to obtain optimal levels for the markers,
therefore a pharmacological treatment is needed in many cases.
Statins reduce the LDL level [43]. PCSK9 is responsible for the degradation of
the LDL receptors and as a consequence evolocumab, one of the drugs based
on a PCSK9 inhibitor, lowers LDL cholesterol level [44].
In order to target triglyceride levels, other drugs, like fibrates or niacin, are also
needed. Controversies arose on the safety of niacine and fibrates [45] and new
therapeutic solutions targeting the triglyceride levels are now under develop-
ment.
In the light of the tight bond between apoC-III and triglyceride, targeting
apoC-III could be a viable option to lower the triglyceride concentration in dys-
lipidemic individuals. Indeed apoC-III-synthesis-inhibition has been proven to
reduce triglyceride levels in a phase 2 clinical study [46].
1.3.3 Kinetic studies in metabolic diseases
Here we report some examples of past discoveries obtained through the study of
lipoprotein or apolipoprotein kinetics that enrich our knowledge on metabolic
diseases.
It is important to remember that apoB is a core part of chylomicrons and of apoB-
100-containing lipoproteins, therefore kinetics of lipoproteins can be studied by
taking track of the content of apolipoprotein B in lipoprotein group fractions.
Lipoprotein kinetics
Type II diabetes Individuals with noninsulin-dependent type II diabetes were
compared with normal individuals [47]. The type-II-diabetic individuals had
higher VLDL apoB levels, due to an increased production rate and decreased
conversion from IDL to LDL. IDL apoB concentration was also higher due to a
decreased transfer to LDL particles. Finally clearance rate for LDL apoB was
significantly lower in diabetic patients.
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Abdominal obesity In a study cohort with abdominally obese people, elim-
ination rate of VLDL particles correlates more strongly with the triglyceride
concentration than the production rate of triglyceride-rich-lipoproteins [26].
Apolipoprotein kinetics
ApoC-III Compared to nonobese individuals, viscerally obese individuals
had higher concentration of VLDL-apoC-III, with lower clearance rate and
higher production rate. Lower clearance rate was observed also for the HDL-
apoC-III, with a coupled increase in the concentration [48].
In a comparative study between normal and type-2 diabetic with matched body
weight, diabetic individuals showed an increased secretion rate and clearance
rate of apoC-III compared to the non-diabetic group [49].
ApoE VLDL-apoE kinetics and HDL-apoE kinetics was studied in a group
of obese individuals (BMI > 29.3). The 7 individuals with type II diabetes
showed increased levels of VLDL-apoE and HDL apoE, both of which tied to
an increased production rate [50].
1.4 Glimpses of the experimental design and math-
ematical tools
As pointed out in Section 1.3, only studying the concentration of apolipopro-
teins and lipoproteins might not be enough to unravel the mechanisms involved
in the metabolic disease, therefore we study their kinetics.
Here, for simplicity purposes, we will be specifically talking about apolipopro-
teins. It is worth noting that the experimental set-up and the mathematical
framework is the same when lipoprotein kinetics is analysed.
Experimental set-up Noninvasive measurements can only take place in the
blood, therefore we are limited to sampling blood to access apolipoprotein
concentration and we would like to use these measurements to reconstruct their
lifecycle.
In order to do this, we choose to study the lifecycle of leucine, an amino acid,
which is a building block of all proteins, including apolipoproteins.
An isotope of the naturally occurring leucine is given with a bolus injection to
the patients and we quantify at different time points its occurrence in the free
state and its presence in the apolipoproteins. These studies are called tracer-
tracee studies, in that an inserted material (tracer) is used to take track of the
dynamics of another material (tracee).
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There are two different important stages for the isotope leucine: a state when it
is free and a state in which it has been incorporated into the apolipoproteins.
The transition from one state to another requires a description. This is resolved
through a structural model, which can simply be thought as a picture describing
the different stages of the molecule.
Mathematical framework Since our goal is quantification of the biologically
interesting parameters, we need a mathematical description of the model to
assess how the different states (parts of the picture) are quantitatively connected
to each other. In our case, the biological process can be described as a linear
system of differential equations, where the independent variable is time and
the dependent variables are the quantities of leucine in different stages. The
parameters of the system quantify the speed of transition from one stage to
another.
We shall also decide how to think about the individuals in the study. Are they
just separate individuals, each of them exhibiting a behaviour totally untied
from the others, or are they part of a bigger family, each of the individual
behaviours being a slight variation on the common distribution of a larger
population? Therefore we choose a statistical model for the parameters of the
system.
Our key question is on the quantification of the parameters for production and
elimination of the apolipoproteins. While the combination of the mathematical
model for the kinetics and statistical model for the parameters of the system
gives birth to a family of distributions, we are interested in the specific set of
parameters that maximizes the probability of observing exactly the specific
dataset of measurements (maximum likelihood estimation approach).
Therefore the last ingredient, the experimental data shall be incorporated. Op-
timization algorithms exploit our mathematical and statistical description in
order to obtain the sought-after parameter estimates from the data.
As seen in Section 1.1.2 nonlinear mixed effects models (NLMEM) encapsulate
the mathematical description of the system into a statistical framework for the
population behaviour as and exploits optimization algorithm for parameter
estimation.
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2 Aims and outline of the the-
sis
In this chapter, we lay out the aims of the thesis and subsequently we present its
outline, focusing on the specific strategies we adopted to fulfil the overarching
mathematical aim.
2.1 Aims of the thesis
Some biological questions would remain unanswered if mathematics and statis-
tics would not provide the tools for describing biological mechanisms and make
inference on them.
The overall aim of the thesis is to develop mathematical models and tools to
describe the kinetics of three apolipoproteins of interest (apoC-III, apoE and
apoA4) and to apply them to clinical data. While a model for apoC-III kinet-
ics had been already developed [48] and then later applied to the study of
VLDL-apoE kinetics [51], to our knowledge a general model for overall apoE
kinetics and for apoA4 kinetics had not yet been developed. Because of the
above-mentioned versatily of the model in [48], one aim was to understand
whether a suitable version of this model could be generalized to study the
kinetics of all the three apolipoproteins. Additionally, we investigated whether
the choices on the statistical model (variance-covariance matrix structure and
error model) could also be generalized. The developed framework, complete
with structural and statistical model, will be presented in Paper I. Let us now
dive into the specific biological questions related to the datasets that we are
analysing and the needs from which they arise and keep in mind that these are
just some of the questions that can be answered with the tools developed in this
thesis.
Despite the abundance of the biological questions that stems from the connec-
tion between lipid metabolism and metabolic diseases, very few population
kinetic studies have been focusing on lipoproteins and the number of kinetic
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studies on apolipoproteins is even more scarce.
As seen in Section 1.2, apolipoproteins confer properties to the lipid carrying
particles where they are attached.
Apolipoprotein C-III (ApoCIII or apoC-III) inhibits LPL, therefore reducing the
clearance of triglyceride in the blood [52].
Apolipoprotein E instead facilitates the removal of triglyceride particles, since
its presence is necessary so triglyceride containing lipoproteins can bind to the
LDL receptor and abandon the blood stream [52]. Apolipoprotein A4 increases
insulin secretion [23], therefore playing an important role in metabolic diseases.
Our focus will revolve around these three apolipoproteins with the overall aim
of deepening our understanding of their kinetics and of how they are nestled in
the frame of metabolic impairments.
First let us zoom in our apolipoproteins and obtain the most information on this
piece of the puzzle. The antagonism between apoC-III and apoE could suggest
the existence of a relationship between their kinetics parameters, but so far their
kinetics have been studied separately. The novel experimental set-up of our data
allows us to study apoA4, apoC-III and apoE in a composite manner, with the
goal of uncovering relationships among their kinetics parameters. This aspect
will be tackled in Section 5.2, through the study of the correlation structure of
these parameters at baseline.
Now let us zoom out and find where our apolipoproteins of interest belong in
the overall puzzle of lipid metabolism. This will be analysed by studying the
correlation structure of the apolipoproteins kinetics parameters with individual
characteristics of the subjects undergoing the experiment at baseline; this con-
tent is also discussed in Section 5.2.
The last biological interest is to check whether three different treatments affect
the apolipoprotein kinetics.
More than once, hypercaloric intake of fructose has been shown to generate an
increase in the triglyceride content in the blood.
This is confirmed by the large study [53], that our dataset is part of, where an
additional increase in apoC-III content is resulted from the treatment. We are
interested in investigating whether an increased production rate or a decreased
clearance rate has produced this effect and whether additional effects can be
found in the kinetics of apoA4 and apoE. While the overall effects for the three
apolipoproteins will be described in Paper I, the results concerning apoC-III
will be integrated with the results concerning lipoprotein kinetics in Paper II,
where we elucidate the previously unknown mechanism behind the increase in
triglyceride concentration consequent to fructose treatments.
Evolucomab and liraglutide are two drugs to treat aspects of type II diabetes.
Evolucomab (Evo) inhibits PCSK9, therefore increasing clearance of LDL parti-
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cles, by reducing the degradation of LDL receptors. Since apoE binds with LDL
receptors, we expect an effect of the drug on apoE kinetics and therefore investi-
gate on it. The results about the effects of evolocumab on the apolipoprotein E
and C-III kinetics will be shown and discussed in Paper III.
The action of liraglutide increases insulin secretion and therefore lowers glucose
blood levels. The cascade of insulin signalling impacts lipid metabolism. It has
already been shown in the larger study [54] that a liraglutide treatment posi-
tively affects postprandial lipid metabolism. Our question is on how apolipopro-
tein kinetics is impacted. This content will be show in Section 5.3.3.
2.2 Outline of the thesis
We can describe the apolipoprotein kinetics with a compartmental model and
in so doing, moving our biological interest into the mathematical world. The
manuscripts are addressed to a public interested in biology, therefore the math-
ematical details are left out of the manuscripts and can be found in Chapters 3
and 4.
Section 3.1 will depict the mathematical theory on the compartmental mod-
els and present the alternative approaches for the estimation of the parame-
ters (standard two stage method (STS) and nonlinear mixed effects models
(NLMEM)). In Section 3.2 we present the datasets used in this work together
with the model structure and the software used. Chapter 4 is dedicated to the
choice of the model. First in Section 4.1 we introduce the proposed model. In
Section 4.2 the above-mentioned two alternative methods for parameter estima-
tion (STS and NLMEM) will be explored and we justify our choice of NLMEM
as method of estimation.
In Section 4.3 we argue some choices on the model.
From a biological perspective two quantities (the amount of free leucine in the
blood and the amount of leucine in each apolipoprotein) are equally eligible
to be parameters of the model. We investigate whether choosing one over the
other has effect on the goodness of fit of the model.
We then compare two possible descriptions of the system: one model encom-
passing all the apolipoproteins (forcing some of the parameters to have the
same distribution)(combined model) or a model where each apolipoprotein
kinetics is analysed separately.
A common variance-covariance structure is needed in order to analyse the data
across different visits or studies together. While it might be reasonable to decide
for the most general model, a parsimony principle would lead us to have a more
specific variance-covariance structure. Therefore we investigate the datasets
and design the minimal variance-covariance matrix that is able to encompass
the relevant correlations between random effects found in the different studies.
In Section 4.4 we walk through the process of validation of the model.
Chapter 5 describes thoroughly the biological results. The abundance of our
data, that contains information for three apolipoproteins, has allowed us to anal-
yse the kinetics of apoA4, apoC-III and apoE for the same group of individuals.
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Nevertheless not all the results are so novel and interesting for the scientific
world to be extrapolated as manuscripts. Indeed, the analysis of the results
is a necessary step for the selection of the new findings. Section 5.1 describes
the steps of this analysis and illustrates the visual tools used to perform them.
The remaining sections of this chapter describe the results with the aid of these
tools.
Finally Chapter 6 summarizes the findings in the manuscripts, while Chapter 7
offers perspectives on the outlined work and make suggestions about further
work in the research domain.
3 Methodology
In the human body, at any given moment, we assume that quantities are in a
steady state.
This means that, if we were to measure the amount of apolipoproteins in the
blood at two time points, we would only detect a negligible difference.
This is the reason behind the use of isotopes of naturally occurring molecules
for the study of the kinetics. We assume that the labelled material behaves
exactly as the natural occurring one and that its insertion does not influence the
behaviour of the system.
The inference on the kinetics is the bridge between the datasets and a deeper
understanding of reality. A model is necessary for this purpose; it can be
thought as a simplification of a phenomenon, with the goal of shading light
on it. After depicting the general framework for the inference on kinetics in
Section 3.1, elements specific to this thesis will be presented in Section 3.2.1: the
available datasets for the analysis and the software used.
3.1 Inference on the kinetics
In this section we will first introduce the needed ingredients for the inference
on the kinetics: compartmental models and datasets. We will then explain the
model development process and familiarize more with two alternative ways
for performing the parameter estimation, STS and NLMEM, already introduced
in Section 1.1. The second one will be explained more in detail and alternative
algorithms for its implementation will be laid out. We will then look into the
concepts of identifiability and observability and finally present an overview of
the tools to diagnose the goodness of fit of the model.
3.1.1 Compartmental models
The following definition of compartmental models is rearranged from [55].
A compartmental model represents the overall description of a system with
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multiple compartments and highlights the movement of material among them.
Compartments are units with homogeneous chemical and physical characteris-
tics and kinetic properties, not necessarily correspondent to a unified space.
Let us introduce the compartmental model for leucine kinetics, which will be
then used in Section 4.2. This represents part of the bigger model used to de-
scribe apolipoprotein kinetics, which will be presented in Section 4.1. Each of
Figure 3.1: Model for natural leucine kinetics
the node in the graph represents a compartment. kij indicates the transfer rate
from compartment j to compartment i and k0j indicates the transfer rate from
compartment j to a compartment external to the system. In order to reduce
the number of parameters in the model, some relations among the parameters
of the system are enforced, as seen in equations 4.9 and 4.10 for the bigger
compartmental model and the removal from compartment 2 k02 is fixed to
0.011, as done in [56]. The compartmental model can be described with the
mathematical language as a system of differential equations:
dQ1
dt
= U − (k12 + k01 + k31) ∗Q1(t) + k13 ∗Q3(t) + k12 ∗Q2(t)
dQ2
dt
= −(k12 + 0.011) ∗Q2(t) + k12 ∗Q1(t)
dQ3
dt
= −(k13 + k43) ∗Q3(t) + k31 ∗Q1(t) + 0.1 ∗ k43 ∗Q4(t)
dQ4
dt
= −0.1 ∗ k43 ∗Q4(t) + k43 ∗Q3(t)
Leucine kinetics is only one example of a biological mechanism that can be
thought of as a deterministic process, where the future state can be predicted if
we know the current state and the evolution law. This concept is crystallized in
the mathematical language as a dynamical process [57]. A system of differential
equations describes the law and the initial condition signifies the current state,
as in equations 1.5 and 1.6.
In this work we do not aim at merely describing the biological process, but we
are interested in the behaviour of the specific individuals in the experiments
and in generalized the obtained results to the population of individuals where
they belong. Therefore while the structural model and equations remain the
same for all the individuals, the parameters vary for each individual i and we
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indicate this with a subscript:
dxi (t)
dt
= f (xi(t), t,ki) (3.1)
xi (t0) = x0 (ki) (3.2)
f is the function that explains how the quantities in the system change over
time and ki is the parameter vector for the i-th individual.
We call x, the vector of dependent variables, state vector and xi is the state
vector for the i-th individual.
The kinetics of the state vector is highly dependent on the parameters of the
system ki.
For the endogenous leucine model:
x = [Q1, Q2, Q3, Q4] (3.3)
k = [U, k01, k12, k13, k31, k43] (3.4)
In case the system of equations 3.1 describes the change in the quantity in one
compartment in terms of the inflow from other compartments and the outflow
from the compartment, the equations are called mass balance equations. If
each component of f is a function linear in the components of x the differential
system of equations is called linear.
Fixed and random effects The individual i could be considered as a fixed
effect if the overall group of individuals exhaust our research interest [7]. In
this case each individual i could be considered separately and the individual
level would represent a fixed effect. Alternatively, all the individuals in the
study could be thought of as a sample of a larger population, that we are
interested in analysing and the population would be a fixed effect. In this case,
the individual level represents a random effect and the model has mixed effects,
in that it comprehends parameters which are fixed, relative to the fixed effects
(the population) and random, relative to the random effects (the deviation of
each individual from the population average).
Dataset Compartmental models are used in conjunction with experimental
data. The trials usually involve the insertion of a material in the body, since
a perturbation shall occur in order to detect modifications in the body. The
material could be a drug or an isotope of a naturally occurring quantity. De-
pending on the methods of administration, the information on this quantity
can be included in the initial condition, as in our case, or incorporated in the
function f . The system of differential equations represents the structural model.
The goal is to make inference on the system, therefore we need a dataset. Since
our interest is not only on the kinetics for one individual, but on the general
behaviour of the population, the experiment to generate data will comprehend
several individuals. The study of a dynamical system requires that each in-
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dividual is sampled at different time points. Let i denote the index for the
i-th individual, with i = 1, ..., N . Let tij denote the time point for the j-th
measurement for the i-th individual with ij = 0, ...,mi.
The dataset d will consist of di, denoting the data for the i-th individual. d is
written in bold because several quantities could be measured.
di = {dij}j=1,...,mi (3.5)
We can approximate the data with a function of the state vector, model approxi-
mation, therefore we can denote it as a measurement function and write:
yij = h
(
xi
(
tij
))
(3.6)
The data dij will differ from the model approximation yij due to the measure-
ment error, that we will later encounter.
3.1.2 Choice of the model
The overall goal is making quantitative inference on the kinetics. In order to do
this a model is required. The choice of the model is done in two phases:
1. Model development: develop a suitable structural model, a set of equa-
tions that can describe the biological process and a statistical model for
the parameters, if the estimation method requires it,
2. Model validation: test whether the goodness of fit of the model is consis-
tent through application to other datasets.
In few cases, this could be a linear process, where phase 2 follows phase 1, but
in general this can be thought as a circular process. If the model developed in
the first step cannot describe the datasets used in the second phase, information
gathered in this step can be used to update the structural and statistical model,
in phase 1.
Knowledge about biology is used in the structural model development process.
The selected model is chosen based on the fit of the model with one or more
datasets, therefore parameter estimation is involved in the process. One can
adjust the structural model or the statistical model based on the information
delivered by the diagnostics tools.
A general aim is that the model is not specific to the dataset under analysis but
that its validity continue to hold for different datasets.
Therefore model validation consists in applying the model to one or more
datasets different to the one used for model development and check whether
the dataset can be described with the same model.
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3.1.3 Estimation methods
We will assume that the structural model is fixed, so our goal is to explore the
statistical model, if needed, and estimate the average behaviour of the popula-
tion and its inter-individual variability.
Standard two stage (STS) method
A naive way to get this information is called standard two stage (STS) method.
Here we do not choose any statistical model and we use the following proce-
dure:
1. The parameters ki are estimated separately for each individual, by min-
imizing the sum of the squared difference between the data and the
approximation given by the model.
2. Statistical analysis are performed to obtain the mean of the parameter
across the study individuals and its standard deviation.
While the simplicity of this approach makes it highly suitable for implementa-
tion, there are some drawbacks that must be taken into account:
1. Obtaining a good estimate of the population average can be difficult when
the model comprehends more than one parameter. The standard deviation
of the parameter across the different individuals might be very high since
the parameter estimates are independent for each individual
2. Time series must contain a big number of time points for each individual
[58], since the parameter estimate for the i-th individual can only make
use of data for that individual.
Nonlinear mixed effects models
We can imagine that the study individual do not exhaust the extent of our
research questions and that they are a sample from a larger population, therefore
the individual parameters and the error would contain random components,
due to the fact that they must behave according to the distribution of the larger
population. To integrate this in the modelling framework, we introduce a
statistical model, which encompasses choices for the parameter distribution
and for the error model.
Distribution of the parameters We can think of ki, the parameter for the i-th
individual, as a realization of a random variable, containing information on the
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population average and on the inter-individual variability. This approach is
called nonlinear mixed effects models (NLMEM), since it encompasses fixed
effects (population averages) and random effects (random parameters for the
specific individual).
Almquist et al. introduced a modification to the NLMEM algorithm [14]. Wang
neatly explains how the formulas used in NONMEM, one of the most used
software for NLMEM, are derived [59]. Most of the formulas in this section are
from these two main sources.
A common choice for the parameter distribution is the log-normal.
ki = k ∗ eηi (3.7)
where ηi is the vector of the individual random effects. In case of the log-normal
distribution ηi is a realization of a normal variable with mean 0 and variance-
covariance matrix given by Ω.
Error model choices The randomness in the individual parameter is not the
only source of volatility.
In fact the error also contains a random part; the j-th observation of the i-th
individual at time tij is the sum of the measurement function based on the
model evaluated at time tij plus an error component.
dij = h (xi (tij)) + eij (3.8)
In Monolix, there are several choices of error model. We describe here the
choices that we have contemplated in this thesis. The error model for each of
the components of the measurement function h might differ from each other,
therefore here we report the formulas for the error model for one component of
h, and for the sake of simplicity we will denoted it as h.
1. constant: the error does not depend on h, but it is constant.
dij = h (xi (tj)) + aeij (3.9)
2. proportional: the error is proportional to h. The bigger the value of the
function, the bigger the error that is expected.
dij = h (xi (tj)) + bh (xi (tj)) eij (3.10)
3. combined1: this error model combines the two previous ones, entailing
that the total measurement error can be written as a combination of a
component which is independent on h and another that is proportional to
h.
dij = h (xi (tj)) + (a+ bh (xi (tj))) eij (3.11)
In each of the preceding error models the random component is represented
3.1. Inference on the kinetics 23
by eij , which is a realization of a random variable. In Monolix eij for each
of the components of the measurement function is a standardized Gaussian
random variable; in a more general setting eij can encompass the error compo-
nent for the different measurement functions as in 3.9. A common choice for
the distribution of this random vector is the normal distribution, with mean
0 and variance-covariance matrix given byR. We assume in this case that the
variance-covariance matrix is fixed and does not depend on the individuals nor
on the time point.
The fixed parameters of the model are not limited to the vector of the popula-
tion fixed effect parameters k. In fact the parameters for the inter-individual
variability in the variance-covariance matrix Ω and the ones for the error model
are also fixed effects. We will denote with θ the vector containing all the fixed
parameters of the system. For simplicity purposes, we will explain more in
depth mathematics with the constant error model across all the measurement
functions.
Towards parameter estimation, the likelihood function In order to estimate
the parameters of the model from the experimental data, a maximum likelihood
approach is chosen. The chosen set of parameters will be the one that maximizes
the likelihood of obtaining exactly our dataset, if the system described with that
set of parameters was to be sampled.
The likelihood function can be written in the following way:
L (θ) =
N∏
i=1
∫
p1 (di|θ,ηi) p2 (ηi|θ) dηi (3.12)
where
p1 (di|θ,ηi) =
ni∏
j=1
e−
1
2
ᵀ
ijR
−1ij√
det (2piR)
(3.13)
and
p2 (ηi|θ) = e
− 12ηᵀiΩ−1ηi√
det (2piΩ)
(3.14)
We can rewrite the likelihood function as:
L (θ) =
N∏
i=1
∫
exp (li) dηi (3.15)
with:
li = −1
2
ni∑
j=1
(
ᵀijR
−1ij + logdet (2piR)
)
− 1
2
ηᵀiΩ
−1ηi − 1
2
logdet (2piΩ) (3.16)
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being the individual likelihood function for the i-th individual. There are differ-
ent ways to proceed in the maximum likelihood estimation.
Laplace Approximation We can use the Laplace approximation to approxi-
mate the likelihood function in the following way:
LL (θ) =
N∏
i=1
(
exp (li (η
∗
i ))
(
det[
−∆li (η∗i )
2pi
]
)− 12)
(3.17)
where η∗i is the point which maximizes the individual joint-likelihood li. The
formula contains the Hessian (matrix of the second derivatives) and the gradient
(vector of first derivatives) therefore we need to calculate the first and second
derivatives.
We show the derivation of the individual likelihood function with respect to
the random parameters:
dli
dηik
= −1
2
ni∑
j=1
(
2ᵀijR
−1 dij
dηik
+ ᵀijR
−1 dR
dηik
R−1ij + tr[R−1
dR
dηik
]
)
−ηᵀiΩ−1
dηi
dηik
(3.18)
dij
dηik
are the derivatives of the residuals with respect to the random effects. These
can be written as:
dij
dηik
=
d(dij − yij)
dηik
= −
(
∂h
∂ηik
+
∂h
∂xij
dxij
dηik
)
(3.19)
therefore derivatives of the state variables with respect to the random effects
are needed. We also need the second derivatives of the likelihood function,
therefore we need also second derivatives of the state variables with respect to
the random effects. Additionally mixed derivatives of the state variables with
respect to a component of the fixed parameter vector and a random effect are
also needed. These equations that express the change in the state variable with
respect to the model parameters are called sensitivity equations. The approach
of estimating the gradient with the analytic solution, rather than with numerical
approximation, introduced in Almquist et al. [14], allows for an improved
gradient precision and for reduced computational times.
Not all the parameter estimation algorithms use the same algorithm. In order
to proceed with the calculations in a faster way, some algorithms apply the first
order approximations, that neglects the terms containing the second derivatives.
The FO (First order approximation) calculates the likelihoods by using ηi = 0
for all the individuals, since this is the population mean.
The FOCE (First order conditional estimation) instead calculates the likelihood
at a specific value of ηi that maximizes the individual likelihood, but neglect
the dependency of theR matrix on the random effects. The FOCE-I (FOCE with
interaction) takes into account this dependency.
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The following are the steps of the optimization algorithm. The second step shall
be continued until an established convergence criterion is met.
1. Preliminary step:
(a) initialize the values of the fixed parameters
(b) set the individual random parameters to be 0
2. Fixed parameter search: repeat this step until a chosen convergence crite-
ria is verified
(a) Inner Optimization for each individual:
i. find the random parameter maximizing the individual log-likelihood
function
(b) find the population parameters maximizing the population likeli-
hood, based on the Laplace approximation
SAEM algorithm
We have used the software Monolix to perform our analysis.
Monolix uses a different algorithm to obtain the parameter set that maximizes
the likelihood function. The algorithm, called SAEM (Stochastic Approximation
of Expectation Maximization) is a modified version of the EM (Expectation
Maximization) algorithm.
The goal of the EM algorithm, usually used for incomplete data, is to obtain the
maximum likelihood parameter estimate. The EM algorithm consists of two
steps, iterated until convergence is reached:
1. E-step: we calculate a conditional expectation of the likelihood with
respect to the current conditional distribution of the latent variables given
the state vector and the current value for the fixed parameter vector .
2. M-step: we maximize the function obtained in the E-step in order to set
the new value for the next iteration of the algorithm.
The random effects, which cannot be observed, can be considered as latent vari-
ables, therefore the EM algorithm is a suitable solution for parameter estimation
in NLMEM. The SAEM algorithm presents a modification of the EM algorithm,
with a stochastic twist: it adds a simulation step in the expectation phase. The
full algorithm and proof of its convergence can be found here [60].
The parameter search implements a Monte Carlo Markov Chain (MCMC)
method to draw samples from the conditional distributions. There are two
phases of the parameter search: the exploratory phase, which aims at exploring
the parameter space to find a good first approximation of the parameter set and
the smoothing phase, that ensures a smoother convergence to the parameter
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vector that maximizes the population likelihood. Here we report the algorithm
for the fixed effects parameters for a simple model, where the parameters for
inter-individual variability and error model have been fixed therefore the vector
θ containing the parameters that shall be estimated only encompasses the fixed
population parameters k .
The subscripts for θ in the algorithm equations will signify the two phases of
the algorithm (E stands for exploration and S for smoothing). Here is how the
complete algorithm works:
1. Preliminary step:
(a) initialize the values of the parameters θ0E
2. Exploratory phase: for l in {1, . . . ,ME}
(a) draw ψi from p
(
ψ|di, θlE
)
for i in 1, ..., N with MCMC
(b) estimate the new population parameters through
θl+1E =
1
N
N∑
i=1
ψi (3.20)
(c) update l: l = l + 1
3. Smoothing phase: set l = 0 and continue until convergence is reached:
(a) θ0S = θ
ME
E where M is the number of iterations in the exploratory
phase
(b) draw ψi from p
(
ψ|di, θlS
)
for i in 1, ..., N with MCMC
(c) estimate the new population parameters through:
θl+1S = θ
l
S +
1
l
[
1
N
N∑
i=1
ψ
(l)
i − θlS
]
(3.21)
(d) update l: l = l + 1
3.1.4 Identifiability and observability
The measurement functions are not always enough to uniquely determine the
parameters or the states of a model.
That’s where the study of identifiability and observability analysis comes into
play. Hermann et al. in [61] and Villaverde in [62] clearly outline these concepts,
that we report here.
A dynamical system can be described as a system of differential equations with
an initial condition and a measurement function, as in equations 3.1, 3.2 and 3.6.
A model is globally observable when the initial condition uniquely determines
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the measurement function vector.
In mathematical terms we can state it as follows:
∀x0,k with dx
0
dt
= f(x0 (t) , t,k) and x0(0) = x0 (k)
@x1,k1 with
dx1
dt
= f(x1 (t) , t,k1) and x1(0) = x1 (k1)
and x1 (k1) 6= x0 (k) and k1 6= k and h(x0 (t)) = h(x1 (t)) ∀t ≥ t0
(3.22)
The parameter ke, e-th component of k, of a model is locally structurally identi-
fiable if for all the parameter sets, there is no parameter vector with a different
value for ke in a neighbourhood of this parameter, so that the value of the
measurement vector is the same for all the time points.
In mathematical terms we can write it as:
∀ x0,k ∃ U(k) such that @ k1 in U(k) with ke 6= ke1 such that
h(x0 (t)) = h(x1 (t)) ∀ t ≥ t0 with
dx0
dt
= f(x0 (t) , t,k) and x0(0) = x0 (k) and
dx1
dt
= f(x1 (t) , t,k1) and x1(0) = x1 (k1)
(3.23)
A model is locally structural identifiable if all the parameters are locally struc-
tural identifiable.
Local structural identifiability can be seen as a special case of observability, if
we consider for each component of the parameter vector k additional states kei
with dk
e
i
dt = 0.
The identifiability and observability analysis can be performed by a software.
Our choice was the software presented in [63].
3.1.5 Model diagnostics and model selection criteria
Diagnostics through comparison of model approximation and observed data
There are several tools for model evaluation based on the comparison of the
observed data with the model-based approximation.
Individual fit The easiest way to do such a comparison is plotting for each
individual the model-generated curve together with the observed data. This
is a good way of checking whether the model could fit well the data for the
specific individual. If we look at this graph for each of the individuals we can
check whether the model can fit all of them.
When using this tool for model selection, care must be applied. Usually focusing
just on one individual and its potential worse fit might not be a good measure
to choose one model over another. The choice based on this graph can be jus-
tified only if this worse fit is consistent across many individuals. Very similar
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models, on the other side, do not provide fits which are consistently worse for
many individuals. Therefore the individual fit is usually not a sufficient tool to
discriminate between two similar models.
When the number of individuals in the sample is high, checking the individ-
ual graphs becomes expensive. Two additional drawbacks of this diagnostic
tool are that it is difficult to grasp from these graphs whether there exists a
tendency of the model to overestimate or underestimate the observed data and
whether the model can describe the average behaviour of the population. Two
additional graphs, observed vs predicted data and tracer curves, respectively
address the first and second newly cited drawbacks. Since they both consider
all the individuals simultaneously, they are also less expensive to look at.
Observed vs predicted data This scatter plot shows on the x axis the observed
data and on the y axis the model prediction. A y = x line enables to compare
whether the observed and predicted values are similar. This graph can highlight
whether the observed data points are consistently underestimated or overesti-
mated.
Tracer curves For each of the time points the average observed data and the
standard deviation is calculated across the individuals. The individual model-
predicted curves are averaged. The graph shows the mean (± standard de-
viation) for each time point and the averaged individual curves , therefore it
indicates whether the model can predict the average behaviour of the popula-
tion.
This graph does not provide specific information about the individual fit.
Visual Predictive Check While the individual fit graph can highlight the
goodness of fit for a single individual and the tracer curves show if the model
can explain the average behaviour of the individuals, the Visual Predictive
Check (VPC) does not take into account the individual parameters but it simu-
lates data to check whether the observed median, the 90% percentile and the
10% percentile are inside of the confidence intervals of the respective percentiles
originated with simulated data. The simulated data takes into account the
statistical model, the inter-individual variability and the error model.
The time points of the observed data are divided into different bins. New indi-
viduals are simulated from the distributions and 10%, 50% and 90% percentile
are calculated for the chosen bins. A 90% confidence interval is then built for
these percentiles for the bins. The same percentiles are calculated for the ob-
served data for the same bins and a graph is built to check whether the observed
percentiles for different time points are inside of the confidence interval of the
simulated percentiles.
This graph is informative, because it shows whether the observed percentiles are
in line with the ones from the simulated data. This tells whether the observed
data can be statistically expected from the model, so the information delivered
in this graph is much deeper than the one obtained from the tracer curve, that
only explains whether the average population behaviour can be described by
averaging the individual curves.
In case the individuals are subject to different dosages, the VPC might not
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be informative. Therefore a prediction-corrected VPC has been introduced to
normalize the value in the bins [64] and keep the predictive value of the VPC.
Akaike information criterion (AIC) The AIC takes into account m, the num-
ber of parameters of the model and ln(L∗), the logarithm of the maximum
likelihood estimate:
AIC = 2m− 2ln(L∗) (3.24)
The connected strategy is to choose the model that minimizes the AIC. Models
with a low number of parameters and high value of the likelihood function are
advantaged. A principle of parsimony is perfectly married to the maximum
likelihood principle: if two models have the same maximum likelihood value,
the one with a lower number of parameters will be chosen and if two models
have the same number of parameters, the one with the highest maximum
likelihood will be chosen.
The AIC springs from information theory and can be seen as a modification
to the Kullback-Leibler divergence, that measures the discrepancy of a model
with respect to the true function that generated the data. More details on the
theoretical foundations of the principle can be found in [65] and in [66], where
the principle is defined.
Checking the range of the parameters NLMEM describes the individual be-
haviour as a slight variation on the average population behaviour. After obtain-
ing the individual estimates, it is good practice to check their standard deviation.
In fact, in some cases, the abundance of parameters with random effects could
have the variability gravitate in a cluster of parameters and reduce the variabil-
ity of other parameters. One shall therefore check whether the obtained range
of parameters is in line with the expected range.
Additional model selection guiding measures The choice of the model is not
only concerning the structural model. More specific choices shall be made on
the statistical model: the error model and the statistical model for the popula-
tion parameters, which entails the choice of the variance-covariance matrix and
of the distribution for the parameters. Therefore the three following measures
are also important:
Relative standard error of the error model parameters The confidence interval
range for a parameter is dependent on the standard error, therefore a big rela-
tive standard error (r.s.e) indicates a big uncertainty in the parameter estimates.
The model might be too complex to support for a more certain estimate of
the parameter, therefore parameters with a small value and big r.s.e. are good
candidates to be removed from the error model to simplify it.
Correlation between the random effects The standard choice in Monolix is to
have a diagonal variance-covariance matrix. If a specific test, described later,
shows that two random effects might be correlated, one can modify the variance-
covariance matrix structure and add the hypothesized correlation couple.
30 3. Methodology
Normality of the random effects The model rests on the assumption that the ran-
dom parameter have a normal distribution therefore one has to check whether
this assumption truly holds.
These features will be explained more in detail during the model selection
process.
Motivation behind the choice of the figures and tables shown
The different statistical models analysed in Section 4.3 do not show significant
differences in the individual fit of the model to the data. Therefore the only
individual curve shown is one comparing the STS estimation with the NLMEM
estimation.
The lack of discrepancy between the different models is shown through the
overlapping of the tracer curves. Other curves (observable vs predicted or VPC)
are shown when they provide us further elements to lead to a decision on the
model.
3.2 Data and tools
In this section, we present the datasets and tools that have made the findings in
this thesis possible. The specific experiments analysed will be presented shortly.
Mathematical modelling is the tool to make inference on the biologically inter-
esting questions: a software is needed to perform the analysis. Space will be
given to it in this section.
3.2.1 Datasets
The study design and experimental procedure is not in the scope of this thesis.
The experimental setup of the tracer-tracee study is explained in Section 1.4
and mathematically described in Section 4.1, therefore the description of the
datasets in this section will be short, briefly describe the treatment and focus on
the quality of the datasets.
Fructose This study is part of a bigger study [53].
Before and after the 12 weeks of intervention, when 75 g of fructose were
consumed daily, the subjects underwent the tracer-tracee experiment. They
received a fat-rich meal, 2 hours after being injected with a bolus of leucine
(time 0) and blood samples were taken at different time points. The chemical
analysis of the samples, explained in detail in the Appendix, resulted in the
time-series data used for the parameter estimation.
Table 3.1 shows the composition of the data for the different apolipoproteins.
While apoC-III and apoE kinetic parameters analysis can rely on 20 individuals,
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apoA4 apoA4 apoC-III apoC-III apoE apoE
visit 1 visit 2 visit 1 visit 2 visit 1 visit 2
n Subjects 17.0 17.0 20.0 20.0 20.0 20.0
tot ape(leucine) 304.0 304.0 358.0 358.0 358.0 358.0
av ape(leucine) 17.9 17.9 17.9 17.9 17.9 17.9
tot ape(apo) 94.0 99.0 163.0 168.0 171.0 180.0
av ape(apo) 5.5 5.8 8.2 8.4 8.6 9.0
tot apo pool 169.0 168.0 197.0 196.0 193.0 199.0
av apo pool 9.9 9.9 9.8 9.8 9.6 10.0
tot points 567.0 571.0 718.0 722.0 722.0 737.0
av points 33.4 33.6 35.9 36.1 36.1 36.8
Table 3.1: For each apolipoprotein and for each visit, number of individuals, time points,
average number of time points for the different measurements and total number of data
points for fructose treatment data; ape stands for atom percent excess: while ape(leucine)
indicates m1 in equation 4.40, ape(apo) indicates m2 as described in equation 4.41
only 17 individuals are suitable for the kinetic study of apoA4. As will be
clear in Section 4.1, where the model and the measurement functions will be
described, the measurement denoted with ape(apo) is the key measurement for
the estimation of the kinetic parameters. The average number of points for this
measurement is low in apoA4 for both visits, therefore the quality of data for
apoA4 is low.
Evolocumab The dataset is part of a bigger study [67].
Before and after 12 weeks of evolocumab treatment, the subjects received a
fat-rich meal and a bolus injection of leucine. The chemical analysis of the blood
samples extracted after the injection generated time series data for the different
individuals. 14 subjects fulfilled the study criteria and of these, 13 individuals
had a suitable data configuration to perform the kinetic analysis.
Conjunctively with the evolocumab treatment, the subjects introduced statin
and metformin. Table 3.2 describes the data for the different apolipoproteins in
terms of number of datapoints. Similarly to the fructose study, the low number
of average points for ape(apo) implicates a low quality of data for apoA4.
Liraglutide The dataset is part of a previous study [54].
Before and after 16 weeks of liraglutide treatment, on background of metformin
and statins, the subjects underwent the tracer-tracee experiment. Analysis of
the chemical composition of the data generated the times-series data used for
the parameter estimation.
The composition of the data in terms of abundance of data points is described
in Table 3.3 for the different apolipoproteins. Consistently with the fructose and
evolocumab experiments, the average number of data points for apoA4 is lower
than the ones for apoC-III and apo-E, therefore the quality of data for apoA4 is
lower than the one for apoC-III and apoE.
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apoA4 apoA4 apoC-III apoC-III apoE apoE
visit 1 visit 2 visit 1 visit 2 visit 1 visit 2
n Subjects 13.0 13.0 13.0 13.0 13.0 13.0
tot ape(leucine) 214.0 209.0 214.0 209.0 214.0 209.0
av ape(leucine) 16.5 16.1 16.5 16.1 16.5 16.1
tot ape(apo) 80.0 77.0 100.0 97.0 109.0 109.0
av ape(apo) 6.2 5.9 7.7 7.5 8.4 8.4
tot apo pool 128.0 129.0 126.0 126.0 128.0 129.0
av apo pool 9.8 9.9 9.7 9.7 9.8 9.9
tot points 422.0 415.0 440.0 432.0 451.0 447.0
av points 32.5 31.9 33.8 33.2 34.7 34.4
Table 3.2: For each apolipoprotein and for each visit, number of individuals, time
points, average number of time points for the different measurements and total number
of data points for evolocumab treatment data; ape stands for atom percent excess:
while ape(leucine) indicates m1 in equation 4.40, ape(apo) indicates m2 as described in
equation 4.41
3.2.2 Monolix
The software used for the estimation of the parameters is Monolix2019R2. More
on the algorithm that is implemented in the software has been described in the
Section 3.1.3.
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apoA4 apoA4 apoC-III apoC-III apoE apoE
visit 1 visit 2 visit 1 visit 2 visit 1 visit 2
n Subjects 12.0 12.0 13.0 13.0 13.0 13.0
tot ape(leucine) 214.0 214.0 232.0 232.0 232.0 232.0
av ape(leucine) 17.8 17.8 17.8 17.8 17.8 17.8
tot ape(apo) 86.0 74.0 95.0 100.0 108.0 112.0
av ape(apo) 7.2 6.2 7.3 7.7 8.3 8.6
tot apo pool 120.0 120.0 130.0 130.0 130.0 129.0
av apo pool 10.0 10.0 10.0 10.0 10.0 9.9
tot points 420.0 408.0 457.0 462.0 470.0 473.0
av points 35.0 34.0 35.2 35.5 36.2 36.4
Table 3.3: For each apolipoprotein and for each visit, number of individuals, time points,
average number of time points for the different measurements and total number of
data points for liraglutide treatment data; ape stands for atom percent excess: while
ape(leucine) indicates m1 in equation 4.40, ape(apo) indicates m2 as described in equa-
tion 4.41
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4 Choice of the model
In this chapter, the proposed model will be introduced in Section 4.1 and in
Section 4.2 it will be used to analyse the kinetics of the three apolipoproteins
(A4, C-III and E); here the two alternative methods of estimation (STS method
and NLMEM) will be compared. In Section 4.3, the analysis will focus on
specific choices on the structural and statistical model and in Section 4.4 the
model will be validated. Some of the choices can be generalized for the three
apolipoproteins, while for the remaining ones, a procedure will be offered to
navigate among the different options, so that the choice will be perfectly suitable
for the dataset under analysis.
4.1 Proposed model
Motivation
The model developed in [48] to describe apolipoprotein C-III kinetics, has been
previously used to describe apoE-VLDL kinetics as well [51]. We suggest that with
some adjustments, this model can be used for apoC-III, total apoE plasma kinetics
and apoA4 kinetics.
Approach
• introduce some modifications to the model in [48]
• segment the datasets so that one part can be used for model development
and the remaining part can be used for model validation
• decide between the two approaches for parameter estimation (STS and
NLMEM)
• investigate choices for the structural model and statistical model in Section
4.3.
• in Section 4.4 validate the model with the choices established in Section 4.3
Since leucine is a building block of all the synthetized proteins, this amino
acid is a common choice to take track of the synthesis and elimination of pro-
teins. In fact we use an isotope of this molecule (labelled molecule) to study
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the kinetics of the apolipoproteins. By tracking the quantity of free labelled
leucine and of labelled leucine in the apolipoproteins and comparing these
to the natural occurring quantities we can extract information on the whole
kinetics of apolipoproteins. Production rate, time delay until the release in the
blood stream and clearance from the blood can be inferred by analysing the
time series measurements.
Important to notice is that the inference on the lifecycle of apolipoproteins is
only possible through the combination of tracer/tracee experiments, mathe-
matical modelling and statistical inference, since the journey of the leucine
molecule can be described in a mathematical language and statistics bridges
this description with the experimental data in order to obtain a quantitative
understanding of the system.
Figure 4.1: Model for endogenous leucine, from its free state in the blood (compartment
1) to the release into the blood as part of the apolipoproteins (compartment 5)
Compartmental models for tracer-tracee experiments We describe the kinet-
ics of the naturally occurring leucine for the i-th individual with a system of
differential equations:
dQi (t)
dt
= f (Q(t), t,ki) +U i (4.1)
Qi (t0) = Qi,0 (ki) (4.2)
We assume that the insertion of the labelled leucine q does not perturb the
behaviour of the system, therefore the total quantity q +Q will follow the same
dynamics of Q alone. The only difference between Q and q consists in the
input. While the blood compartment of natural occurring leucine Q1 is always
replenished with a constant input U (in compact vectorial form denoted by U ,
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see Figure 4.1), the labelled leucine input only occurs at the initial time point.
The stable-isotope of leucine is administered with an injection and this implies a
quick distribution of the material, therefore all the quantity administered can be
thought of as concentrated at the initial time. In light of this, we can incorporate
the information about the dosage in the initial condition.
d (Q+ q)i (t)
dt
= f ((Q+ q)i (t), t,ki) +U i (4.3)
(Q+ q)i (t0) = (Q+ q)i,0 (ki) (4.4)
When describing biochemical mechanisms, a linear differential equation is often
enough to describe the dependency of the change in the substrate concentration
with respect to its concentration. Biochemical reactions are subject to saturation
if too much material overloads the enzymatic action; in this case one would
need to switch from linearity to a more complex mathematical description (for
example Michaelis-Menten kinetics). The tracer-tracee study is designed to
avoid saturation, therefore the inserted quantity q will be much smaller than
the naturally occurring quantity Q (q << Q).
This ensures the linearity of f with respect to the state variables and the param-
eters ki.
Because of linearity, the state variables q and Q will appear separately and not
be mixed, therefore we can split the system of differential equations in two twin
systems, one where only Q appears (tracee equations) and the other where only
q appears (tracer equations), that will be solved together with the respective
initial conditions. The assumption that the naturally occurring quantities are
at steady state implies that the change over time is zero, therefore the system
of differential equation for the natural leucine Q will turn into a system of
equations 4.6.
dqi (t)
dt
= f (qi(t), t,ki) (4.5)
0 = f (Qi(t), t,ki) +U i (4.6)
qi (t0) = qi,0 (ki) (4.7)
Qi (t0) = Qi,0 (ki) (4.8)
The model used for the description of the kinetics of leucine from the free state
to its being part of the apolipoproteins, shown in Figure 4.1, is based on the
model used in [48] to describe the kinetics of apolipoprotein C-III. Because of
the lack of mathematical details in the paper where the model is presented,
we hypothesize that the model is congruent to the one in Figure 1(B) in the
article, therefore we conclude that two of our choices, pointed out below, are
modifications of the original model. Before elucidating them, let us explain the
meaning of the different compartments.
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Leucine kinetics Free leucine kinetics can be described with 4 compartments.
Compartment 1 represents free leucine in the blood; the different phases of
the leucine decay curve suggest that there is an exchange with a free leucine
pool, represented by compartments 3 and 4. Compartment 2 has a fast material
exchange with compartment 1 and is where free leucine will flow before entering
the liver. In order to reduce the number of parameters in the model, some
relations among the parameters of the system are fixed.
Population kinetics Apolipoprotein E, C-III and A4 are released in the blood
after being produced in the liver (apoE and apoC-III) and in the intestine
(apoA4). Protein synthesis and secretion from free leucine is represented by
a series of 5 delay compartments. The delay is connected to a compartment
representing the apolipoproteins in the blood.
Our datasets comprehend only measurements of apolipoproteins, but do not
specify whether the apolipoproteins are free or located in any specific lipopro-
tein group (LDL, VLDL, IDL or HDL). One could hypothesize a more complex
model where the compartments representing the apolipoproteins release into
the blood are two or more and these could indicate the different lipoproteins
group (for example VLDL1 and VLDL2). The resolution of our data is not
enough to support a more complex model, therefore we choose to settle for the
one here described, where only one compartment represents the apolipopro-
teins in the blood.
Model equations Two relationships are enforced to limit the number of possi-
ble parameters, as done in [68]:
k21 = k12 (4.9)
k34 = 0.1k43 (4.10)
The tracer kinetics is described by the following system of differential equations:
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dq1
dt
= k13 ∗ q3(t) + k12 ∗ q2(t)− (k12 + k01 + k31) ∗ q1(t) (4.11)
dq2
dt
= k12 ∗ q1(t)− (k11 + kD12) ∗ q2(t) (4.12)
dq3
dt
= k13 ∗ q1(t) + 0.1 ∗ k43 ∗ q4(t)− (k13 + k43) ∗ q3(t) (4.13)
dq4
dt
= k43 ∗ q3(t)− 0.1 ∗ k43 ∗ q4(t) (4.14)
dqD1
dt
= kD12 ∗ q2(t)− kD ∗ qD1(t) (4.15)
dqD2
dt
= kD ∗ qD1(t)− kD ∗ qD2(t) (4.16)
dqD3
dt
= kD ∗ qD2(t)− kD ∗ qD3(t) (4.17)
dqD4
dt
= kD ∗ qD3(t)− kD ∗ qD4(t) (4.18)
dqD5
dt
= kD ∗ qD4(t)− kD ∗ qD5(t) (4.19)
dq5
dt
= kD ∗ qD5(t)− k05 ∗ q5(t) (4.20)
(4.21)
The following system describes the tracee kinetics. In compartment 1 there is a
constant input of material.
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dQ1
dt
= U + k13 ∗Q3(t) + k12 ∗Q2(t)− (k12 + k01 + k31) ∗Q1(t) (4.22)
dQ2
dt
= k12 ∗Qtoliver1 (t)− (k12 + kD12) ∗Q2(t) (4.23)
dQ3
dt
= k13 ∗Q1(t) + 0.1 ∗ k43 ∗Q4(t)− (k13 + k43) ∗Q3(t) (4.24)
dQ4
dt
= k43 ∗Q3(t)− 0.1 ∗ k43 ∗Q4(t) (4.25)
dQD1
dt
= kD12 ∗Q2(t)− kD ∗QD1(t) (4.26)
dQD2
dt
= kD ∗QD1(t)− kD ∗QD2(t) (4.27)
dQD3
dt
= kD ∗QD2(t)− kD ∗QD3(t) (4.28)
dQD4
dt
= kD ∗QD3(t)− kD ∗QD4(t) (4.29)
dQD5
dt
= kD ∗QD4(t)− kD ∗QD5(t) (4.30)
dQ5
dt
= kD ∗QD5(t)− k05 ∗Q5(t) (4.31)
where Qtoliver1 indicates all the leucine that flow to the liver, since this is not
limited to the leucine in the blood. Since the tracee system is in steady state,
the system of differential equations becomes a system of linear equations and
solving for the state variables (obtaining the analytical solution for the linear
system of equations) provides the quantities of the tracee at steady state as a
function of the model parameters.
Qtoliver1 =
Q1
p1
(4.32)
Q2 =
k12 ∗Qtoliver1
kD12 + k12
(4.33)
QD1 =
kD12 ∗Q2
kD
(4.34)
QD2 = QD1 (4.35)
QD3 = QD2 (4.36)
QD4 = QD3 (4.37)
QD5 = QD4 (4.38)
Q5 =
kD ∗QD5
k05
(4.39)
Since the free leucine pool in the blood is not the only source of leucine for
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the assembly of apolipoproteins, we insert p1 in the equation, which indicates
the proportion of leucine in the apolipoproteins coming from the above cited
source. We assume that this proportion is tracer-free.
The measurement functions for the tracer-tracee study can be described as
follow:
m1(t) = 100
q1(t)
q1(t) +Q1
(4.40)
m2(t) = 100
q5(t)
q5(t) +Q5
(4.41)
m3(t) = Q5 (4.42)
Differences between the model and the original model The proposed model
is based on the one suggested in [48]; two are the main differences:
1. Parameter k01: in the original model, no exit was contemplated from the
compartment representing the free leucine in the blood, supposedly due
to a different approach to data analysis: supposedly they could have used
use the first two measurement functions ( in equations 4.40 and 4.41 ) for
the parameter estimation and subsequently adjusted the results with the
pool size. We introduce the parameter k01, which can also be found in [49]
in a model describing the apoC-III kinetics.
2. Analytic solution for Q5: In the measurement functions Q1 and Q5 ap-
pear. Apparently, one could have chosen Q1 and Q5 as model parameters
and it would have not been necessary to introduce the steady state ap-
proximation to write Q5 as a function of Q1. Instead in our model Q1 is
a parameter and an additional parameter p1 is introduced. While this
could look like an unnecessary move, the choice is justified by the fact that
Q5 is measured, therefore we choose not to enforce a distribution on it.
The validity of this choice will be proven when in the Section 4.3 we will
compare the Q1 and the Q5 model. Having Q5 as a parameter worsens
the predictability of the model.
Biological parameters We are interested in knowing how fast the apolipopro-
teins are produced and how fast they are removed from the blood stream. This
is what determines their concentration, which is also the object of our interest.
Therefore while continuing to look at the other parameters from a mathemat-
ical modelling perspective, the true biological concern will be regarding the
fractional catabolic rate, the pool size and the secretion rate. In the study time
is measured in hours (h). The dosage, initial condition of q1 in the system of
differential equation, is provided in mg leucine/kg; all the quantities of the
system are therefore normalized with the weight. The state variables in the
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system have therefore unity of measure mg leucine/kg. In order to obtain the
biologically relevant parameters with the right unity of measure, we need to
rescale the parameters of the system. Let R leu
apo
be the amount of mg of leucine
in each mg of apolipoprotein. Let 0.45 be the conversion rate between body
weight in kg and dL of blood in the body.
FCR = k05 ∗ 24 (4.43)
PS = Q5/R leu
apo
/0.45 (4.44)
SR = k05 ∗Q5 ∗ 24/R leu
apo
(4.45)
Now the unities of measure for FCR, PS and SR are respectively pools/day, mg
apolipoprotein/dL, mg apolipoprotein/(day kg).
Identifiability and Observability analysis of the model The model is locally
structurally identifiable, which means that all the parameters are locally struc-
turally identifiable. The parameters attaining the leucine pool are nonobservable
and so are the state variables for these compartments.
Segmenting the data for model selection and model validation The total
available data consists of three datasets. Therefore we segment it in two parts:
the dataset regarding the fructose intervention experiment will be used for the
choice of the method (Section 4.2) and model development (Section 4.3) and
the experiments concerning the evolocumab and liraglutide treatments will be
used for model validation purposes (Section 4.4). Since the first dataset is more
abundant, we aim at discovering more possible features through this dataset
and then at transferring this knowledge to the more restricted second and third
dataset, from which characteristic features might not be noticed.
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4.2 Choice of the method
Motivation
Scrutinize different methods for the parameter estimation
Approach
• investigate NLMEM vs STS for leucine model
• investigate NLMEM vs STS vs mixed approach for the complete apolipopro-
tein data
Result
• results for rich datasets are comparable for STS and NLMEM, even though
STS shows a bigger variability
• in case of poor datasets, NLMEM exploits information about the population
behaviour to help fitting the data, therefore rendering an improved fit.
For the leucine compartments
We have performed the STS estimation and the NLMEM estimation first by
taking into account only the data corresponding to the measurements of the
enrichment (the ratio of tracer over the whole amount (tracer + tracee)) of free
leucine (equation 4.40).
The compartmental model for the free endogenous leucine alone consists of the
compartments 1-4 of the apolipoprotein model (see Figure 3.1 at page 18).
For identifiability purposes [56], the removal rate from compartment 2 k02 had
been fixed to 0.011. We can assume that the system describing endogenous
leucine is in steady state, while the one for the tracer, labelled leucine, will be
described with a similar system of equations without natural leucine replen-
ishment U , and therefore we will choose to consider Q1 (instead of U ) as a
parameter of the model.
By analysing the results in the tables and figures, we can make the observations:
• the standard deviation of the parameter estimate for the STS method is
much larger (see Table 4.1). This is confirmed in the scatter plot of the
individual parameter estimates (Figure 4.2).
• NLMEM have slightly more dispersed values in the observed vs predicted
data (Figure 4.3). The lack of structure for the parameters leads STS to
overfitting, while this cannot be true for NLMEM, since the parameters
must belong to the same distribution.
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parameter STS mean NLMEM mean STS std NLMEM std
k01 3.54 3.23 1.08 0.31
k12 3.15 2.45 1.69 0.48
k13 1.73 2.35 0.81 0.24
k31 2.79 2.33 1.43 0.13
k43 1.04 0.91 1.16 0.01
Q1 1.97 2.1 0.67 0.32
Table 4.1: Mean and standard deviation of the kinetic parameters for the leucine model
estimated with STS and with NLMEM. Unity of measure for Q1 is mg leucine/kg, while
for the remaining parameters is 1/h
Figure 4.2: Scatter plot of the individual parameter estimates for the free leucine com-
partment
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Figure 4.3: Plot of observed vs predicted data with the two estimation methods for the
free leucine compartment measurement (equation 4.40) at visit one
STS NLMEM mixed STS NLMEM mixed
parameters mean mean mean std std std
apoA4 FCR 3.62 3.81 3.85 1.49 0.51 0.02
apoA4 PS 5.39 5.4 5.4 1.46 1.34 1.43
apoA4 SR 8.6 9.06 9.34 4.26 1.8 2.44
apoC-III FCR 1.51 1.5 1.46 0.54 0.4 0.29
apoC-III PS 6.65 6.62 6.65 2.83 2.83 2.95
apoC-III SR 4.1 4.12 4.21 1.24 1.1 1.67
apoE FCR 4.65 4.61 4.6 1.18 0.9 1.04
apoE PS 2.81 2.81 2.83 1.19 1.25 1.3
apoE SR 5.56 5.59 5.66 1.73 1.93 2.17
Table 4.2: Mean and standard deviation of the kinetic parameters for the different
apolipoproteins estimated with STS, NLMEM and mixed approach. FCR, PS and SR have
respectively unity of measure pools/day, mg apolipoprotein and mg apolipoprotein/day
For the full model
Here we compare three alternative methods. Additionally to the STS method
and NLMEM framework, we will also use a mixed approach, where all the
parameters, apart from the parameters directly related to the compartment
5, will be estimated with STS. Only the elimination rate of apolipoproteins
(k05) and the rate of release of the apolipoproteins into the blood (kD) will be
estimated with a NLMEM approach. This choice stems from the fact that these
two parameters are the ones who mostly affect the biological parameters, as it
can be seen from equations 4.43 - 4.45 at page 42
From this comparison, the following observations stem:
• As seen in the leucine case, we can notice from Table 4.2 a bigger standard
deviation for the parameter estimates with STS method.
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Figure 4.4: Scatter plot of the individual parameter estimate for the biological parameters
for apoA4 at visit 1 with x and y axis indicating the used method for estimation (first row:
x axis NLMEM, y axis STS; second row: x axis STS y axis mixed; third row: x axis mixed,
y axis NLMEM). The digits in the title express the Pearson’s correlation coefficient of
the two estimates. FCR, PS and SR have respectively unity of measure pools/day, mg
apolipoprotein and mg apolipoprotein/day
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Figure 4.5: Curve estimated with NLMEM (and average curve from the other individuals
in the population) and curve estimated with STS approach. NLMEM can make fruit of
the population information to overcome scarcity of data for one individual.
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Figure 4.6: Scatter plot of the individual parameter estimate for the biological parameters
for apoE at visit 1 with x and y axis indicating the used method for estimation (first row:
x axis NLMEM, y axis STS; second row: x axis STS y axis mixed; third row: x axis mixed,
y axis NLMEM). The digits in the title express the Pearson’s correlation coefficient of
the two estimates. FCR, PS and SR have respectively unity of measure pools/day, mg
apolipoprotein and mg apolipoprotein/day
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• While for apoE the parameter estimates with the different methods corre-
late strongly with each other and they mostly fall along the line y = x (as
shown in Figure 4.6), the same does not hold for apoA4 (as seen in Figure
4.4). In fact for apoA4 different methods yield quite diverse estimates,
with lower correlation coefficient (Pearson’s r as shown in the figure) and
that do not fall onto the line y = x. This is due to the low quality of the
apoA4 data. In fact, as shown in Table 3.1 on page 31, apoA4 analysis
can rely on a smaller number of points for the enrichment curve. ApoC-III
has similar quality of data as apoE and the different estimates correlate
significantly with each other and fall along the line y = x, therefore, since
the corresponding graph for apoC-III would only confirm what already
stated for apoE, we omit to show it.
• The example individual in Figure 4.5 crystallizes one of the strengths
of NLMEM. Here we can see that while STS cannot go beyond the data
that it is analysing, NLMEM can transcend the limitations of the specific
individual and make fruit of the overall information from the population
to obtain the estimates and this leads to a more reasonable dynamics for
the data.
Conclusions Based on the observations above, we conclude that the best
estimation method is NLMEM. In fact it can exploit the overall signal coming
from the population in order to fit the individual data, which is especially useful
when data are scarce.
4.3 Model development
In this section we will explore the model selection process. Each subsection will
inspect one specific choice in this procedure. A box will introduce the main
points of the exploration: the motivation, the approach used and the results.
Details will be given in the remaining part of the subsection.
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4.3.1 Choice between Q1 and Q5 model
Motivation
From the biological point of view two different quantities are eligible to be used
as parameters. Even though, we would like to avoid enforcing a probability
distribution on the measured quantity (Q5) as pointed out in Section 4.1, analysis
shows better observability for the model that includes Q5 as a parameter.
Approach
Perform the kinetic analysis with the two alternative models
Result
Results are very similar for the estimated parameters, but we choose the model
where Q1 is a parameter due to better predictability
More on the motivation In the model equations at page 40 Q1 (the steady
state amount of free leucine in the blood) appears as a parameter and we de-
scribe Q5 (the steady state quantity of leucine in apolipoproteins) as a function
of Q1, scaled by the parameters of the system. We compare the identifiability
and observability for this model, already discussed at the end of Section 4.1
with the one of an alternative model where instead Q5 is a parameter in the
system and Q1 is a function of Q5.
While grandly the results about identifiability and observability coincide be-
tween the two models (both are identifiable and the leucine compartments and
leucine parameters are non-observable), one detail differs, in that Q5 is observ-
able in the model containing it as a parameter, while Q1 is not in the model
where it appears as a parameter. This stems from the fact that Q5 is actually
measured. While we are aware that having Q5 as a parameter would mean
enforcing a distribution for this parameter, we explore whether this model, with
Q5 as a parameter, Q5 model, can yield an improvement over the model with
Q1 as a parameter, the Q1 model.
Analysis of the results The parameter estimates are very similar to each other
as shown in Figure 4.7. Therefore we choose to look at the VPC (visual predictive
checkplot).
While the comparison of the parameter estimates doesn’t highlight clear dif-
ferences between the two models, discrimination between the fit of the two
models comes from the comparison of the VPCs, in Figure 4.8. The plot for
the Q5 model indicates in fact that the simulated data using the estimated pa-
rameters would yield too much variability, so that the 90th percentile of the
observed data (blue upper segmented curve) would not fall inside of the 90
percent confidence interval of the 90th percentile (blue curve); in fact due to the
blue curve falling inside of the red area (for the 90th percentile of the median),
the red area delimited by the blue curve is highlighted in bright red.
4.3. Model development 51
Figure 4.7: Scatter plot of the individual parameter estimates with the two models
for the biological parameters at visit 1. On the x axis the Q1 model and on the y axis
the Q5 model. FCR, PS and SR have respectively unity of measure pools/day, mg
apolipoprotein and mg apolipoprotein/day
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Figure 4.8: Prediction-corrected visual predictive checkplots for apoE at visit 1. On the
left the VPC for the Q1 model and on the right the one for the Q5 model. The VPCs for
m1(equation 4.40), m2(equation 4.41) and m3(equation 4.42) respectively in rows 1,2 and
3.
Conclusion The Q5 model shows a reduced predictability, therefore our final
choice is the Q1 model.
4.3.2 Choice between the combined and the separate model
Motivation
Since the unique study design allows to consider the kinetics of all the apolipopro-
teins simultaneously, we contemplate using a combined model, where we analyse
the complete data set.
Approach
Perform the kinetic analysis with the two alternative models, a combined model,
where all the measurements comprehending the three apolipoproteins are anal-
ysed simultaneously, and separate model, where each apolipoprotein is studied
separately
Result
• no substantial difference can be noticed from the results
• we opt for the separate model in order to maximize the information obtained
from the dataset.
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Figure 4.9: Scatter plot for the individual estimates of the biological parameters at
visit one. On the x axis the separate model and on the y axis the combined one. FCR,
PS and SR have respectively unity of measure pools/day, mg apolipoprotein and mg
apolipoprotein/day
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Figure 4.10: Tracer curves for the three apolipoproteins (the rows 1,2,3 show apoE, apoC3
and apoA4 respectively, with columns 1,2,3 showing the logarithm of the enrichment
of leucine (logarithm of m1 in equation 4.40), the enrichment of the apolipoprotein (m2
in equation 4.41) and the apolipoprotein pool size (m3 in equation 4.42)), with the two
different methods for visit one. The curves (pink one representing the separate model
and grey one the combined model) almost overlap with each other. The observed data
are presented as mean and the error bars represent the standard deviation.
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Analysis of the results As seen in the scatter plot for the individual estimates
of the biological parameters (Figure 4.9) the estimates are comparable between
the two different models.
The tracer curves in Figure 4.10 are almost overlapping, showing that both of
the models can describe well the average behaviour of the individuals in our
data sets.
Conclusion No considerable differences are noticeable from the use of the
combined model instead of the separate one.
The choice between the two models, therefore, is dependent solely on the
quality of the data. When using the combined model, we need to use the data
for the three apolipoproteins together. As seen in Table 3.1 on page 31 three
individuals with complete set of data for apoE and apoC3 lack suitable data
for apoA4, therefore we choose the separate model, in that it permits for a
maximization of the information extracted from our datasets.
4.3.3 Choice of the error model
Motivation
choice of the error model can influence the range of the parameters, most im-
portantly the parameter k05, which is biologically interesting , since it is tightly
related to FCR (cfr equation 4.43)
Approach
compare different choices for the error model
Result
• simplifying the error model in most of the cases brings a slight improvement
of the Akaike criterion and even when it does not, simplification of the
model is advised
• we follow the criteria suggested in Monolix guidelines, while checking that
the potential worsening of the Akaike criterion is negligible.
Possible choices for the error model and suggested approach The predicted
data from the model do not usually fall exactly onto the observed data. The
discrepancy between the prediction from the model and the observed data is
explained in the model as measurement error (cfr equation 3.8 at page 22).
Let us briefly recapitulate here three of the four different choices for the error
model contemplated in Monolix, already cited in Section 3.1.3 at page 22, where
the mathematical equations can be found:
• constant: the error does not depend on the magnitude of the function
describing the kinetics, but it is constant.
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GEM DDEM
apoA4 visit 1 412.858 412.436
apoA4 visit 2 412.124 420.11
apoC-III visit 1 376.352 372.9
apoC-III visit 2 305.004 305.607
apoE visit 1 279.26 278.119
apoE visit 2 229.673 228.627
Table 4.3: Akaike criterion for the two approaches for the error model for each of the
apolipoproteins. GEM stands for generic error model, while DDEM is the data-driven
error model.
• proportional: the error is proportional to the magnitude of the function.
The bigger the value of the function, the bigger the error that is expected.
• combined1: this error model combines the two previous ones, entailing
that the total measurement error can be written as a combination of a
component which is independent on the magnitude of the function and
another that is proportional to the function.
In order to choose a suitable error model for the data the guidelines of Monolix
suggest to start with the combined1 approach, the more general one, and to try
to remove parameters that have a high relative standard error and compare the
results obtained with different error models. We choose the threshold for the
relative standard error as 100, so we will remove the parameters for the error
model with r.s.e. bigger than 100.
Approach and results We follow exactly the approach suggested. The model
with generic error model (combined1 for all the three measurement functions)
will be called GEM and the model with error model chosen by removing the
parameters with RSE bigger than 100 is called DDEM (data driven error model).
The scatter plot do not show a significant difference between the two error
models. The data driven error model leads to a slight improvement of the
Akaike criterion in most cases.
For apoC-III visit 2 the data driven error model has a slightly worse Akaike
criterion, but the difference is negligible.
The difference between the data driven error model and the generic one for
apoA4 at visit 2 is the largest. Here, though, the relative standard error of the
parameter ( more than 8e15) and its value (about 2e-16) calls for a simplification
of the model. The following table shows the chosen error model for the different
apolipoproteins and the different visits.
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Figure 4.11: Scatter plot for the individual estimates of the biological parameters for visit
1. On the x axis is the estimate with the DDEM, while the y axis provides the estimate
with the GEM model. FCR, PS and SR have respectively unity of measure pools/day,
mg apolipoprotein and mg apolipoprotein/day
apo EM leucine EM apo EM PS
apoA4 visit 1 combined1 combined1 proportional
apoA4 visit 2 combined1 combined1 proportional
apoC-III visit 1 combined1 combined1 proportional
apoC-III visit 2 combined1 constant proportional
apoE visit 1 combined1 combined1 proportional
apoE visit 2 combined1 combined1 proportional
Table 4.4: Error model for the three measurement functions for the data driven error
model. EM leucine stands for the error model of the leucine enrichment. The next two
columns show the error model for the leucine enrichment in the apolipoprotein and for
the pool size.
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4.3.4 Choice among different variance-covariance matrix struc-
tures
Motivation
the choice of the variance-covariance matrix structure can have an impact on the
range of the parameters
Approach
run different calculations with different variance-covariance matrix structures:
• diagonal matrix
• full matrix
• selected matrix according to the significance of the correlations between the
estimated random effects
• a minimal variance-covariance matrix dictated by the correlations in com-
mon for most of the apolipoproteins
Result
• even though an intuitive approach would be to choose as variance-
covariance matrix the one suggested by analysing the p-values of the sug-
gested correlations, this might not be the best choice
• poor data can neglect highlighting a possible correlation structure
Variance-covariance matrix in Monolix In the NLMEM approach a big role
is played by the variance-covariance matrix. This encompasses possible correla-
tions among the parameters for the system.
A significant correlation between two variables indicate that the magnitude
of the variables are related to one another; a positive (negative) correlation
between variable A and B highlights that when variable A has large values, B
will have large (small) values and when A has small values, B will have small
(large) values. Correlations between two variables do not imply causality, but
the relationship could possibly be investigated with further experiments to
uncover this possible connections.
The correlations between the random parameters are encoded in the variance-
covariance matrix. As a standard choice in Monolix the variance-covariance
matrix is diagonal (does not contain any correlation between the random param-
eters) and correlations can be added manually. In Monolix, correlations in the
variance-covariance matrix are transitive; if the correlations between variable A
and variable B are inserted in the variance-covariance structure as well as corre-
lation between variable B and variable C, the correlation will be automatically
inserted also between variable A and C. This will create a correlation group in
the variance-covariance matrix consisting of variables A, B and C. In the tab
tests in the result section, Monolix shows the results of the following tests:
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• normality of the random effects
• test to check whether the correlation between two random effects is signif-
icant
While we will go back to the first one later, let us now focus on the second one.
Monolix suggests to use this as a guiding principle on whether correlations shall
be added. One shall check the p-values of the test for the correlation. In case
the p-value for the correlation between a couple of random effects is smaller
than a chosen significance level, we shall try to add a correlation between the
random effects, thereby making the structure of the variance-covariance matrix
more complex. After adding it and performing the calculation one shall check
whether the p-value of the correlation is still smaller than the significance level.
We will continue adding correlation couples until all of the remaining couples
will have p-values for the correlation bigger than the significance value. This
principle with a chosen significance level α = 0.05 will be used to select a
possible variance-covariance matrix for our model (selected). This procedure
will be operated separately for each apolipoprotein and for each visit.
While the diagonal matrix is the simplest variance-covariance matrix possible,
the full matrix is the most complex one. In this case, since the number of pa-
rameters of our compartmental model is 10, each of them having a random
effect, and in consideration of the symmetry of the variance-covariance matrix
we would need to insert and estimate 45 additional parameters.
After running the estimations with the selected approach described above, we
have noticed that despite the diversity of the data for the different apolipopro-
teins, many of the obtained variance-covariance matrices would contain similar
correlation structures. The correlation group k01, p1 and Q1 would be in com-
mon for many apolipoproteins for one or more visits. Therefore, on the side of
the three described approaches (diagonal matrix, full matrix, selected matrix),
we added a fourth one, consisting of this minimal variance-covariance matrix.
Normality test Due to our choice of distribution for the parameters, the esti-
mation algorithm rests on the assumption that the random effects are normally
distributed, while the parameters of our compartmental model are log-normally
distributed.
It is important to check whether this assumption holds.
In case the test delivers non-normality for one or more random effects, we will
test whether removing an outlier will restore the normality of the random effect.
In fact non-normality can in some cases be only due to the extreme value of one
individual [69]. In this case, we do not proceed further with scrutinizing the
model, since we accept that the non-normality is due to only one value far from
the mean. Monolix repeats the test for normality for many different samples
for the individuals, drawn from their conditional distribution. An individual
whose parameter estimate has an extreme value is likely to have an individual
conditional distribution shifted away from the population mean, therefore this
individual could mislead the algorithm to think that the overall distribution
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of the random effect is non-normal, while this conclusion is mainly due to its
extreme distribution.
The removal of the outlier followed by a persisting non-normality for the param-
eter could be a symptom of poor variance-covariance structure or error model,
therefore in this case we will take a closer look and analyse alternative choices
for the error model or for the variance-covariance structure for the model.
apo full diagonal selected minimal
apoA4 visit 1 475.788 411.712 384.764 396.884
apoA4 visit 2 425.951 419.653 404.618 411.388
apoC-III visit 1 510.909 493.955 516.035 478.386
apoC-III visit 2 425.592 408.668 401.507 400.593
apoE visit 1 478.766 403.965 383.994 383.822
apoE visit 2 309.159 314.675 291.059 291.059
Table 4.5: Akaike criterion for the calculations with different variance-covariance matri-
ces. The selected model has variance-covariance matrix where all the possible correlation
couples are analysed and one by one the ones with p-values <0.05 are included, if the
correlations are still valid after inserting the correlation couple. The minimal approach
has a variance-covariance matrix including the correlation group k01, p1 and Q1
Results For many of the occasions, the minimal variance-covariance model
yields the best Akaike criterion (see Table 4.5). Exceptions are the estimations
for apoA4.
For apoA4 in the first visit, the correlation structure (k01, p1 and Q1) would be
suggested by adding the couples with significant correlation, but they would
not be the ones chosen at the beginning, because smaller p-values for other
correlations would have higher priority.
The interesting result here is that for apoA4 in visit 2 the correlation structure
is not suggested by the p-values (p-values for the test of the three couples in
the minimal correlation group are 0.08, 0.15 and 0.14), but when the correlation
structure is added, the correlations become significant. Additionally, we can see
that, despite the rise in the Akaike criterion in the minimal model compared
to the selected model, in the first one all the parameters follow a log-normal
distribution, while in the selected model two parameters fail in the test for
log-normality. This implies that the selection criterion based on the p-values for
the correlation test (denominated by selected) might not bring the most suitable
variance covariance matrix.
For apoE at visit 2 and apoC-III at visit 1, one parameter fails in the test for
log-normality. By removing an outlier, though, none of the random effects fail
to show normality, therefore the choice of the variance-covariance structure is
plausible.
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apo full diagonal selected minimal
apoA4 visit 1 1 0 0 0
apoA4 visit 2 0 1 2 0
apoC-III visit 1 0 1 2 1
apoC-III visit 2 1 2 2 0
apoE visit 1 1 2 0 0
apoE visit 2 2 1 1 1
Table 4.6: For each of the visits and each of the choices for the variance-covariance
matrix, number of random effects that fail in the test for normality
Conclusions Due to the improvement of the Akaike criterion for apoE and
apoC-III and due to the fact that despite the increase in the Akaike criterion,
the correlations in the chosen minimal matrix (k01, p1 and Q1) are significant
for apoA4, we are safe to choose this as the standard choice for the variance-
covariance model.
4.4 Model validation
Motivation
• need to test whether the strategy for choice of error model yield a good fit
also for the remaining datasets
• need to test whether the choice of the variance covariance matrix allows a
good fit for the datasets from the two experiments not used in the model
selection process
Approach
run different calculations with different variance-covariance matrices and error
models:
• general error model (GEM)
• data driven error model (as suggested in Section 4.3.3) (DDEM)
• general error model with the minimal variance-covariance matrix as sug-
gested in Section 4.3.4 (GEM + COV)
• data driven error model with minimal variance-covariance matrix as sug-
gested in Section 4.3.4 (DDEM + COV)
Result
• in most of the cases the best performing model is the DDEM + COV
• this model is not a one-size-fit-all measure, therefore we need to keep a
flexible mindset and do specific adjustments as the specific dataset requires.
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Figure 4.12: Tracer curves for the three apolipoproteins (the rows 1,2,3 show apoE, apoC3
and apoA4 respectively, with columns 1,2,3 showing the log enrichment of leucine, the
enrichment of the apolipoprotein and the apolipoprotein size), with the two different
methods at visit 1 for the evolocumab experiment. The curves (pink, grey, green and
orange representing respectively GEM, DDEM, GEM + COV and DDEM + COV) almost
overlap with each other. The observed data are presented as mean (points), with error
bars representing the standard deviation.
4.4.1 Process and specific results
Evolocumab The Akaike criterion for the DDEM + COV is lower compared
to the one for the other models; only exception is apoA4 at visit one, where the
difference between the Akaike for DDEM and DDEM + COV is not major.
We notice that there are two occurrences where one or more parameters fail to
be proven to have a log-normal distribution. We will consider these separately
and describe our inspection strategy.
The two occurrences are:
ApoE at visit 2: We first remove an individual to check whether the lack of
nonnormality was caused by the presence of an outlier.
Despite removing the outlier, the nonnormality still persists, therefore we chal-
lenge one of our assumptions of our choice of the variance-covariance model.
We remove one of the correlations. Still one of the parameters lacks lognormality.
The nonnormality is though, due to the presence of an outlier. Therefore we
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Figure 4.13: Tracer curves for the three apolipoproteins (the rows 1,2,3 show apoE, apoC3
and apoA4 respectively, with columns 1,2,3 showing the log enrichment of leucine, the
enrichment of the apolipoprotein and the apolipoprotein size), with the two different
methods at visit 2 for the evolocumab experiment. The curves (pink, grey, green and
orange representing respectively GEM, DDEM, GEM + COV and DDEM + COV) almost
overlap with each other. The observed data are presented as mean (points), with error
bars representing the standard deviation.
apo GEM DDEM GEM + COV DDEM + COV
apoA4 visit 1 361.0 361.0 345.0 345.0
apoA4 visit 2 352.0 340.0 345.0 345.0
apoC-III visit 1 286.0 285.0 254.0 254.0
apoC-III visit 2 279.0 221.0 265.0 200.0
apoE visit 1 174.0 173.0 150.0 148.0
apoE visit 2 36.0 35.0 21.0 19.0
Table 4.7: Akaike criterion for each of the visits with different models for the evolocumab
experiment (GEM and DDEM are respectively the generic error model and the data-
driven one, +COV indicates integrating the chosen minimal variance-covariance matrix
in the calculations)
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apo GEM DDEM GEM + COV DDEM + COV
apoA4 visit 1 0 0 0 0
apoA4 visit 2 0 1 1 1
apoC-III visit 1 0 0 0 0
apoC-III visit 2 1 0 2 0
apoE visit 1 1 0 0 0
apoE visit 2 0 1 2 2
Table 4.8: For each of the visits and each of the methods for the evolocumab experiment,
number of random effects that fail in the test for normality
apo GEM DDEM GEM + COV DDEM + COV
apoA4 visit 1 284.0 296.0 281.0 357.0
apoA4 visit 2 179.0 225.0 161.0 233.0
apoC-III visit 1 301.0 296.0 300.0 293.0
apoC-III visit 2 220.0 236.0 231.0 230.0
apoE visit 1 262.0 271.0 260.0 276.0
apoE visit 2 141.0 91.0 189.0 71.0
Table 4.9: Akaike criterion for each of the visits with different models for the liraglutide
experiment (GEM and DDEM are respectively the generic error model and the data-
driven one, +COV indicates integrating the chosen minimal variance-covariance matrix
in the calculations)
accept the model with simplified variance-covariance structure.
ApoA4 at visit 2: Removing the individual with more extreme value for the
parameter does not result in log-normality for all the parameters, therefore we
challenge our model. For the choice of the error model, we had established, by
following the guidelines in Monolix, that an error model shall be simplified if
the relative standard error(rse) of one of its parameters is bigger than 100, as ex-
plained in Section 4.3.3. For apoA4 at the first visit, we had simplified the error
model by eliminating a parameter with rse slightly above the threshold (108).
Now, in order to obtain log-normality for all the parameters, instead of simpli-
fying the variance-covariance structure, as done with the case of apoE visit 2,
we reinsert the parameter for the error model that we had eliminated due to
the selection criteria. Doing so ensures that all the parameters are log-normally
distributed.
Liraglutide The Akaike criterion shows a big improvement for the DDEM +
COV for apoE in visit 2, an improvement for apoC-III at visit 1 and for apoA4 at
visit 2. The other cases will be further analysed together with apoC-III at visit 1,
since it presents a parameter for which the distribution is not log-normal.
ApoE at visit 1 The Akaike criterion does not improve with our choice of the
model and we have one parameter with non log-normal distribution. Since the
simplification for the error model was necessary (the relative standard error of
the removed parameter was above e16), we can now consider DDEM as term of
4.4. Model validation 65
Figure 4.14: Tracer curves for the three apolipoproteins (the rows 1,2,3 show apoE, apoC3
and apoA4 respectively, with columns 1,2,3 showing the log enrichment of leucine, the
enrichment of the apolipoprotein and the apolipoprotein size),with the two different
methods at visit 1 for the liraglutide experiment. The curves (pink, grey, green and
orange representing respectively GEM, DDEM, GEM + COV and DDEM + COV) almost
overlap with each other. The observed data are presented as mean (points), with error
bars representing the standard deviation
apo GEM DDEM GEM + COV DDEM + COV
apoA4 visit 1 0 0 0 0
apoA4 visit 2 0 1 0 1
apoC-III visit 1 0 0 2 1
apoC-III visit 2 1 2 1 2
apoE visit 1 0 0 0 1
apoE visit 2 1 0 1 0
Table 4.10: For each of the visits and each of the methods for the liraglutide experiment,
number of random effects that fail in the test for normality
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Figure 4.15: Tracer curves for the three apolipoproteins (the rows 1,2,3 show apoE, apoC3
and apoA4 respectively, with columns 1,2,3 showing the log enrichment of leucine, the
enrichment of the apolipoprotein and the apolipoprotein size),with the two different
methods at visit 2 for the liraglutide experiment. The curves (pink, grey, green and
orange representing respectively GEM, DDEM, GEM + COV and DDEM + COV) almost
overlap with each other. The observed data are presented as mean (points), with error
bars representing the standard deviation
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comparison. The difference in AIC of DDEM + COV when compared to DDEM
is not so major, so we aim to reach log-normality for all the parameters byre-
moving the outlier. With this step, we obtain lognormality for the distribution
of all the parameters.
ApoC-III at visit 1 Despite the Akaike criterion improves with the DDEM +
COV model, a parameter is not positive in the lognormality test. By removing
an outlier, we obtain lognormality for all the parameters.
ApoC-III at visit 2 The Akaike criterion for DDEM + COV is just slightly worse
than for the more general model and the parameter estimate are similar, there-
fore we do not look further into the model. By removing an outlier, we obtain
normality for all the parameters, therefore we keep this model.
ApoA4 at visit 1 The Akaike criterion for the DDEM + COV is much worse than
the one for GEM and DDEM. We then try a model with simplified variance-
covariance structure. This, while bringing an improvement of the Akaike
criterion, narrows too much down the range for the FCR. Therefore, in this case,
we choose the simplified error model without any correlation structure in the
variance-covariance matrix, DDEM.
ApoA4 at visit 2: Our standard choice for the model (DDEM + COV) has a
much bigger Akaike criterion than GEM + COV. Since the relative standard
error of one of the removed parameters for the error model was not so far
from the threshold (180), we choose to reinsert this parameter again. Since this
brings an improvement in the Akaike criterion (165) and all the parameters are
log-normally distributed, we choose this as the final model.
4.4.2 Conclusions
For most of the apolipoproteins and visits, the model selection choices depicted
in the Section 4.3.3 and Section 4.3.4 (that when combined generate the DDEM
+ COV model) bring to an improvement of Akaike criterion.
In case that this criterion is much worse for the DDEM + COV model compared
to the alternative models, we suggest first to look at the error model, by check-
ing if we have simplified too much (we reinsert one parameter that we had
eliminated, with rse not far from 100). Secondly, we can look at the correlation
structure in the variance-covariance matrix. Can this be simplified?
Another measure of goodness of fit that we always would like to check is the
log-normality of the parameters. First, we shall check whether by removing one
outlier for the specific parameter, the distribution becomes log-normal. In case
this doesn’t happen, we suggest to act on the error model or on the correlation
structure in the variance-covariance matrix.
All in all, only 2 of the 12 occasions (apoA4 at visit 2 for both evolocumab and
liraglutide studies) have required reinserting one parameter for the error model,
for which the relative standard error was bigger than 100 (108 and 180), only
one occasion have required simplifying the correlation structure (evolocumab
for apoE visit 2) and only one occasion have required totally removing the
correlation structure (liraglutide for apoA4 at visit 1).
We conclude therefore that our model choice strategy (DDEM + COV) can
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describe largely the extent of possible behaviours for the apolipoproteins, but
that this is not a one-fix-all measure, therefore the results of the models shall
always be checked and adjustments shall be made to fit to the specificity of the
data.
5 Results
Our conclusions on the physiology behind the changes due to the treatments can
stem only from a thorough analysis of the results of the experiment. Therefore
several facets shall be taken into account:
• correlations at baseline
• overall effects of the treatments
• linearity between individual characteristics (and their changes) to the
kinetic parameters
In this chapter we will first introduce in detail the tools used for each analysis
and then we will use them to facilitate the description of the results of the
experiments.
5.1 Analysis of the results
The analysis of the results entails different parts. First we are interested merely
in analysing the correlation structure among the kinetic parameters and among
the kinetic parameters and the individual characteristics at baseline. Secondly,
we compare whether changes in the kinetic parameters or in the individual
characteristics between before and after the treatment. Lastly, we look at the
correlations between the kinetics parameters and relevant characteristics for
lipid metabolism at baseline and after the treatment and additionally check
whether the changes in the variables are related.
Here we describe which figures and which tables we will use for the analysis of
the different pieces of the puzzle.
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5.1.1 Correlations at baseline
Motivation
Baseline represents the natural state of the individuals, before the treatment
perturbs their system. Therefore monitoring the correlations among the kinetic
parameters and among these parameters and the individual characteristics and
enriches our knowledge on the kinetics of the apolipoproteins. Moreover they
represent a standard against which the correlations at visit 2 shall be compared to
highlight whether the treatment brought disruptions to the system.
Tools
• Table 1
Table 1 In this table, the names of the variables in the significant correlations
couples are shown. Additionally the Pearson’s correlation coefficient (later
referred to as r) and the p-value (later referred to as p) for the significance of
the correlation are shown together with the normalized slope for the linear
regression of the variable as a function of the covariate. One table shows the
correlations among the kinetic parameters and one those among kinetic param-
eters and individual characteristics.
Our chosen significance level is α = 0.05, therefore p-values which are smaller
than this threshold will indicate that the Pearson’s correlation coefficient is
significant. For ease of read purposes, we will abuse the mathematical denota-
tion, by stating that two variables correlate or that a correlation exists between
two variables instead of fully acknowledging that the two variables correlate
significantly or that their Pearson’s r is significant. The same denotation will be
used in Section 5.4.
5.1.2 Effects of the treatment
Motivation
In order to check whether the treatment had an effect on the individual character-
istics or on the kinetic parameters, we need to compare them between before and
after and establish which changes are significant
Tools
• Tables for the individual characteristics and kinetic parameters
• Scatter plots of kinetic parameters and selected individual characteristics
with values before and after the treatment
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Tables to compare between before and after the treatment This table dis-
plays the following elements: the mean and standard deviation of the quantities
for each of the visits (before and after the treatment), the increase in mean in
percentage and the p-value for the paired t.test with null hypothesis being that
there is no change between the two visits.
We provide one table for the kinetic parameters and one for relevant individual
characteristics.
Scatter plots of kinetic parameters and selected individual characteristics
with values before and after the treatment In this plot, x and y axis indi-
cate the value of the variable for the first respectively the second visit. The title
of the picture shows the mean percentage change together with the p-value for
the significance of the change. This represents a visual aid for the table and
helps us to check whether the significance or non significance of the difference
might be due to some outlier. Additionally it raises our awareness on strong
changes in the range of the values for the parameters.
5.1.3 Correlation of kinetic parameters with selected covari-
ates
Motivation
Correlations between covariates and kinetic parameters could be a symptom of
causality, especially if the relation is stable throughout several conditions (before
and after treatment). With the same purpose, monitoring the correlation between
changes for covariates and kinetic parameters is highly important. High triglyc-
eride levels, high LDL levels and low HDL levels are the markers of dyslipidemia,
an hallmark of type-II-diabetes, that increases the risk for cardiovascular diseases
[5]. Therefore we study the correlation of these individual characteristics with the
kinetic parameters.
Tools
• Picture 1
• Picture 2
Picture 1 In Picture 1 the x axis represents the covariate while the y axis repre-
sents the kinetic parameter. For each individual, two points occur, the green one
describing the first visit and the red the second visit. A line of the corresponding
color indicates the linear regression of the kinetic parameter as a function of
the covariate with title to the sub-figure showing the p-values for the two sided
hypothesis test with null hypothesis being that the slope is equal for both the
visits.
In case the p-value is smaller than 0.05, a correlation exists between the two
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variables and it is reasonable to assume a linear relationship between the kinetic
parameter and the covariate.
Picture 2 We look at this plot to check whether the changes of the covariate
and the kinetic parameters correlate or not.
The x axis represents the covariate, while the y axis indicates the kinetic pa-
rameter. In the title the name of the kinetic parameter plotted in the sub-figure
appears, together with the p-value for the test with null hypothesis that the
slope of the regression line is 0. Therefore a p-value smaller than 0.05 indicates
that the correlation coefficient between the two variables is significant.
5.2 Correlations at baseline
Now we shall look at the correlations among kinetics parameters and between
kinetic parameters and the individual characteristics.
5.2.1 Fructose
covariate variable Pearson’s r p-value slope
apoA4 PS apoA4 FCR -0.705 0.002 -0.208
apoA4 SR apoA4 FCR -0.509 0.037 -0.182
apoC-III PS apoC-III FCR -0.668 0.001 -0.261
apoC-III SR apoC-III PS 0.924 <0.001 1.148
apoE SR apoE PS 0.804 <0.001 0.972
apoE PS apoA4 FCR -0.544 0.024 -0.09
apoA4 SR apoA4 PS 0.961 <0.001 1.169
apoE FCR apoC-III FCR 0.541 0.014 0.473
apoE PS apoC-III FCR -0.688 <0.001 -0.311
apoE SR apoC-III FCR -0.482 0.031 -0.263
apoE FCR apoC-III PS -0.535 0.015 -1.197
apoE PS apoC-III PS 0.699 <0.001 0.809
apoE FCR apoC-III SR -0.453 0.045 -0.815
apoE PS apoC-III SR 0.465 0.039 0.432
Table 5.1: Correlations among the kinetic parameters at baseline of the fructose treatment
First let us take a close look at the correlation among the kinetic parameter
for the same apolipoprotein and then enlarging the view to encompass the
relationships among apolipoproteins. ApoA4 and apoC-III pool sizes both
correlate to their respective SR and FCR, but the positive correlation with the
SR is much stronger (for apoA4 r=0.961 and p<0.001 and for apoC-III r=0.924
and p<0.001) than the negative correlation with the FCR (for apoA4 r=-0.705
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and p=0.002 and for apoC-III r=-0.668 and p=0.001). One can notice that the p-
values do not reflect the difference in absolute value of the Pearson’s correlation
coefficient. This is due to the discrepancy of the number of individuals for
whom the two measured apolipoprotein concentrations would represent a
suitable dataset for the analysis (20 for apoC-III and 17 for apoA4) (cfr. Table
3.1 at page 31). We now describe the relationships between kinetic parameters
for different apolipoproteins. ApoA4 appears to be solitary, exhibiting only one
non strong correlation between the FCR and the PS of apoE. Several associations
exist between the parameters for apoE and the ones for apoC-III. Two are the
strongest ones: between apoE PS and apoC-III FCR (r=-0.688 and p<0.001) and
between apoE PS and apoC-III PS (r = 0.699 and p<0.001).
covariate variable Pearson’s r p-value slope
Cholesterol apoC-III FCR -0.71 <0.001 -0.715
Cholesterol apoC-III PS 0.738 <0.001 1.9
Cholesterol apoC-III SR 0.601 0.005 1.245
Cholesterol apoE FCR -0.533 0.016 -0.613
Cholesterol apoE PS 0.638 0.002 1.42
LDL cholesterol apoC-III FCR -0.584 0.007 -0.48
LDL cholesterol apoC-III PS 0.623 0.003 1.309
LDL cholesterol apoC-III SR 0.511 0.021 0.865
LDL cholesterol apoE PS 0.489 0.029 0.89
HDL cholesterol apoA4 PS 0.684 0.002 0.497
HDL cholesterol apoA4 SR 0.646 0.005 0.386
Triglyceride apoC-III FCR -0.542 0.014 -0.219
Triglyceride apoC-III PS 0.865 <0.001 0.895
Triglyceride apoC-III SR 0.792 <0.001 0.659
Triglyceride apoE PS 0.711 <0.001 0.636
Triglyceride apoE SR 0.523 0.018 0.387
ApoA1 apoA4 PS 0.707 0.002 0.999
ApoA1 apoA4 SR 0.688 0.003 0.799
ApoA1 apoE FCR -0.507 0.027 -0.553
Table 5.2: Correlations among the individual characteristics and the kinetic parameters
at baseline of the fructose treatment
Many correlations can be found between the kinetic parameters and the indi-
vidual characteristics.
We can divide the individual characteristics in two groups, according to the
correlation pattern: cholesterol, LDL cholesterol and triglyceride correlate with
many of the kinetic parameters of apoE and apoC-III, while HDL cholesterol
and ApoA1 levels correlate mostly with apoA4 kinetic parameters. We first
describe the first correlation group.
Cholesterol correlates with all the parameters of apoC-III (with FCR r=-0.71 and
p<0.001, with PS r=0.738 and p<0.001 and with SR r=0.601 and p=0.005) and
with the pool size of apoE (p=0.638 with p=0.002). LDL cholesterol correlates
with apoC-III FCR( r=-0.584 with p=0.007) and with apoC-III PS (r=0.623 and
p=0.003). Triglyceride correlates with the pool sizes of apoC-III (r=0.865 and
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p<0.001) and apoE (r=0.711 and p<0.001) and with the SR of apoC-III (r=0.792
and p<0.001). ApoA1 correlates with two kinetic parameters for apoA4: PS (r =
0.707 and p=0.002) and SR ( r=0.688 and p=0.003).
In summary, the pool sizes of all the apolipoproteins is strongly determined by
the SR. ApoC-III PS and apoE PS correlate and both correlate with the apoC-III
FCR.
Triglyceride correlate with apoC-III SR and PS, while LDL cholesterol correlates
with apoC-III PS and FCR.
5.2.2 Evolocumab
covariate variable Pearson’s r p-value slope
apoA4 SR apoA4 PS 0.735 0.004 0.89
apoC-III SR apoC-III PS 0.83 <0.001 0.999
apoE PS apoE FCR -0.579 0.038 -0.265
apoE SR apoE PS 0.924 <0.001 1.126
apoC-III SR apoA4 SR 0.581 0.037 0.582
apoE SR apoA4 SR 0.617 0.025 1.111
apoE FCR apoC-III FCR 0.7 0.008 1.709
Table 5.3: Correlations among the kinetic parameters at baseline of the evolocumab
treatment
For all the apolipoproteins, the pool size correlates positively with the secretion
rate (for apoA4 r=0.735 and p=0.004, for apoC-III r=0.83 and p<0.001 and for
apoE r=0.924 and p<0.001).
Additionally the fractional catabolic rates of apoE and of apoC-III correlate with
each other (r=0.7 and p=0.008).
covariate variable Pearson’s r p-value slope
Weight apoA4 SR -0.61 0.027 -0.971
Cholesterol apoA4 FCR 0.643 0.018 1.468
Cholesterol apoC-III PS 0.63 0.021 1.901
HDL cholesterol apoC-III SR 0.572 0.041 0.68
Triglyceride apoA4 SR 0.692 0.009 0.708
Triglyceride apoC-III PS 0.858 <0.001 1.055
Triglyceride apoC-III SR 0.76 0.003 0.777
ApoA1 apoC-III PS 0.645 0.017 1.44
ApoA1 apoC-III SR 0.769 0.002 1.425
Table 5.4: Correlations among the individual characteristics and the kinetic parameters
at baseline of the evolocumab treatment
The triglyceride levels correlate strongly with apoC-III PS (r=0.858 with p<0.001)
and SR (r=0.76 with p=0.003). They correlate less strongly also with apoA4 SR
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(r=0.692 and p=0.009). An association exists also between apoA1 and apoC-III
SR (r=0.769 with p=0.002).
In summary, the major determinant of the pool size for each apolipoprotein
is the secretion rate. ApoE and apoC-III fractional catabolic rates correlate.
Triglyceride levels correlate with apoC-III PS and secretion rate, as noticed in
the fructose experiment.
5.2.3 Liraglutide
covariate variable Pearson’s r p-value slope
apoA4 SR apoA4 PS 0.993 <0.001 0.981
apoC-III PS apoC-III FCR -0.707 0.007 -0.187
apoC-III SR apoC-III PS 0.965 <0.001 1.109
apoE PS apoE FCR -0.774 0.002 -0.278
apoE SR apoE PS 0.95 <0.001 1.327
apoC-III FCR apoA4 FCR 0.645 0.023 0.182
apoE FCR apoC-III SR -0.579 0.038 -2.666
Table 5.5: Correlations among the kinetic parameters at baseline of the liraglutide
treatment
We can notice strong correlations between the pool sizes of the apolipopro-
teins and their secretion rates, as seen in the other experiments (for apoA4
r=0.993 and p<0.001, for apoC-III r=0.965 and p<0.001 and for apoE r=0.95 with
p<0.001). Additionally apoE PS has a strong correlation with its FCR (r=-0.774
and p=0.002).
covariate variable Pearson’s r p-value slope
HDL cholesterol apoE PS -0.592 0.033 -0.436
HDL cholesterol apoE SR -0.667 0.013 -0.352
Triglyceride apoC-III PS 0.795 0.001 0.778
Triglyceride apoC-III SR 0.775 0.002 0.66
Triglyceride apoE PS 0.6 0.03 0.309
Triglyceride apoE SR 0.651 0.016 0.24
Glucose apoA4 PS 0.705 0.01 0.637
Glucose apoA4 SR 0.713 0.009 0.652
Liver fat apoC-III FCR 0.659 0.014 0.139
Table 5.6: Correlations among the individual characteristics and the kinetic parameters
at baseline of the liraglutide treatment
Once again, we can notice a strong correlation of the triglyceride levels with
apoC-III pool size (r=0.795 with p=0.001) and secretion rate (r=0.775 with
p=0.002). Additionally apoA4 SR correlates with the glucose level (r=0.713
and p=0.009).
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In summary, the stronger determinant of the pool size for all the apolipoproteins
is the secretion rate. ApoE PS does additionally exhibit a strong correlation with
the FCR. Triglyceride levels are strongly correlated with the apoC-III PS and SR.
5.2.4 General conclusions
Across all the studies some correlation patterns remain unvaried. The pool size
of all the apolipoproteins is mostly determined by the secretion rate. In the
fructose and evolocumab studies, associations exist between kinetic parameters
of apoE and of apoC-III.
Triglyceride levels correlate in all the three studies with apoC-III PS and SR.
Weaker correlations exist also in two of the three studies between triglyceride
levels and apoE PS and SR.
In the evolocumab and liraglutide experiment, the individuals are on statin
treatment; this might induce changes in LDL kinetics so the possible link to
apoE and apoC-III kinetics, detectable in the fructose experiment, could be
overshadowed.
The associations between LDL cholesterol and apoC-III in the fructose study
might be secondary to effects on triglyceride. The negative correlation of LDL
cholesterol with apoC-III FCR might be due to the removal of LDL particles
together with apoC-III. This would also explain the positive correlation between
the pool size of apoC-III and the one of LDL.
5.3 Effects of the treatments
A general description of the results of the experiments will be laid out, with
summary focusing only on the kinetic parameters and individual characteristics
whose change between before and after the treatment is significant.
5.3.1 Fructose
General description of results
Individual characteristics The individuals taking part to the experiment had
mean body weight at visit one of around 100 kg. After the treatment they
experience a 0.8 percent body weight increase which is statistically significant,
but not truly biologically relevant. The mean total cholesterol level was 4.63
mmol/L at the first visit and this undergoes a statistically significant increase in
mean of 4 percent, which lacks biological significance. Average LDL cholesterol
level at the beginning of the study was 3.42 mmol/L and becomes 3.51 mmol/L
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visit 1 visit 1 visit 2 visit 2 mean
mean std mean std change p-value
Weight 99.74 12.45 100.56 12.86 1% 0.034
Cholesterol 4.63 0.87 4.81 0.96 4% 0.04
LDL cholesterol 3.42 0.79 3.51 0.82 3% 0.266
HDL cholesterol 1.02 0.36 1.06 0.34 3% 0.192
Triglyceride 1.47 0.69 1.77 0.82 20% 0.001
Glucose 5.48 0.4 5.47 0.32 0% 0.95
Liver fat 6.24 4.83 7.99 5.17 28% <0.001
ApoA1 1.31 0.26 1.4 0.24 6% 0.002
Table 5.7: Comparison of relevant individual characteristics before and after the fructose
experiment. Weight is expressed in kg, cholesterol, LDL cholesterol, HDL cholesterol,
triglyceride and glucose are in mmol/L, while liver fat is in percentage and apoA1 is in
mg/L
visit 1 visit 1 visit 2 visit 2 mean
mean std mean std change p-value
apoA4 FCR 4.14 0.31 4.2 1.28 1% 0.851
apoA4 PS 10.74 2.7 9.33 2.94 -13% 0.036
apoA4 SR 2.34 0.48 1.94 0.31 -17% 0.01
apoC-III FCR 1.43 0.27 1.35 0.33 -6% 0.119
apoC-III PS 8.8 4.26 11.5 4.95 31% <0.001
apoC-III SR 6.34 2.47 7.89 3.02 24% 0.003
apoE FCR 4.83 1.04 4.97 0.96 3% 0.43
apoE Pool 5.71 2.39 5.84 2.08 2% 0.771
apoE SR 1.42 0.49 1.49 0.43 5% 0.581
Table 5.8: Comparison of kinetic parameters before and after the fructose treatment.
FCRs are expressed in pools/day, PS is expressed in mg/dL and SR in mg/( kg day)
after the treatment, this change being not significant. HDL cholesterol level also
undergoes a nonsignificant increase (increase in mean amounts to 3 percent).
The triglyceride level increases considerably (the increase in mean amounts to
20 percent) and significantly. Glucose level stays almost unvaried going from
an average of 5.48 mmol/L to an average of 5.47 mmol/L. Mean liver fat goes
from an average of 6.24% to an average of 8%, thereby experiencing a 28 percent
increase in average which is significant with p-value less than 0.001.
Another significant increase is that of ApoA1 level, going from an average of
1.31 mg/L to an average of 1.4 mg/L, corresponding to 6 percent in average.
Kinetic parameters The kinetic parameters have been calculated as a result of
the tracer-tracee experiment before and after the treatment period. Few parame-
ters have experienced a significant change. ApoA4 FCR has slightly increased
(with 1 percent increase in the mean), while the pool size and the secretion rate
of apoA4 have experienced a statistically significant decrease (respectively of
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Figure 5.1: Kinetic parameters and relevant covariates before (x axis) and after (y axis)
fructose treatment
13 and 17 percent), which, due the proximity of the p-value to the statistical
significance level and due to the scarcity of the apoA4 data, as shown in Table
3.1 at page 31, might not correspond to truly relevant biological results.
ApoC-III FCR has slightly decreased (with a 6 percent decrease in average),
while the pool size and secretion rate of apoC-III have both increased signifi-
cantly (respectively with 31 and 24 percentage increase in average). All of the
kinetic parameters for apoE have experienced an increase, but none of them
were significant. (FCR, PS and SR respectively having a 3, 2 and 5 percent
increase in average).
Figure 5.1 largely confirms the results of the tables. It is interesting to notice
that for apoE pool size there is an outlier, with very high value at the first visit,
that shifts the balance from the common trend of an increase in pool size at the
second visit.
Summary of results for fructose Some individual characteristics have had
considerable changes between the two visits. The most significant one is the
increase in liver fat with 28 percent increase in average (p<0.001). Additionally
we notice an increase in triglyceride with increase in average of 20 percent
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(p=0.0015) and an increase in ApoA1 (increase in average of 6 percent with
p=0.002).
Several kinetic parameters have also been affected by the fructose treatment.
While the results for the apoA4 kinetic parameters might not be reliable due to
the low quality of data, changes in apoC-III kinetic parameters are relevant and
reliable. The most significant one is the increase in apoC-III pool size (increase
in average of 31 percent and p<0.001). An increase in apoC-III secretion rate
(increase in average of 24 percent) is significant with p-value 0.003.
5.3.2 Evolocumab
visit 1 visit 1 visit 2 visit 2 mean
mean SD mean SD change p-value
Weight 84.3 17.5 84.4 16.8 1% 0.95
Cholesterol 4.15 0.546 2.46 0.561 -41% p<0.001
LDL cholesterol 2.3 0.434 0.699 0.362 -70% p<0.001
HDL cholesterol 1.4 0.389 1.64 0.431 17% p<0.001
Triglyceride 1.71 0.553 1.48 0.606 -13% 0.27
Glucose 6.67 0.649 6.96 1.13 4% 0.18
Liverfat 7.59 7.09 7.87 8.31 4% 0.72
ApoA1 142 25.2 152 24.9 7% 0.005
ApoB 79.3 12.8 37.6 9.85 -53% p<0.001
Table 5.9: Comparison of relevant individual characteristics before and after the
evolocumab treatment. Weight is expressed in Kg, cholesterol, LDL cholesterol, HDL
cholesterol, TG and glucose are in mmol/L, while liver fat is in percentage and apoA1
and apoB are in mg/L.
General description of results
Individual characteristics The individuals have an average body weight of
about 84 kg at the beginning of the study and that remains almost unvaried at
the end of the study. Significant differences concern all the cholesterol levels,
with cholesterol, LDL cholesterol, HDL cholesterol undergoing a change in aver-
age respectively amounting -41, -70 and 17 percent. Triglyceride levels vary also
significantly, going from 1.61 mmol/L to 1.32 mmol/L, thereby experiencing
a 14 percent decrease in average. Glucose levels undergo a slight increase in
average amounting 4 percent. Liver fat undergoes a slight decrease in average
(3 percent). ApoB undergoes a significant decrease (with decrease in average of
53 percent). ApoA1 undergoes a significant increase (the average increases by 7
percent).
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visit 1 visit 1 visit 2 visit 2 mean
mean std mean std change p-value
apoA4 FCR 2.28 0.69 2.76 0.62 21% 0.018
apoA4 PS 12.5 5.01 13.3 3.92 6% 0.35
apoA4 SR 1.46 0.48 1.94 0.62 33% 0.005
apoC-III FCR 1.33 0.33 1.47 0.31 10% 0.03
apoC-III PS 11.52 4.58 10.03 5.55 -13% 0.252
apoC-III SR 7.82 2.58 7.35 3.06 -6% 0.564
apoE FCR 6.22 0.64 9.01 1.8 45% <0.001
apoE PS 3.65 0.82 2.43 0.78 -33% 0.001
apoE SR 1.19 0.22 1.12 0.3 -6% 0.494
Table 5.10: Comparison of kinetic parameters before and after the evolocumab treatment.
FCRs are expressed in pools/day, PS is expressed in mg/dL and SR in mg/( Kg day)
Kinetic parameters ApoA4 experiences significant increases in FCR and SR,
the increase in average respectively amounting to 21 and 33 percent (p-values
respectively 0.018 and 0.005). Due to the low quality of the apoA4 data, these
changes might not be reliable. ApoA4 pool size increases in average by 6
percent, this change being non significant.
The fractional catabolic rate of apoC-III increases significantly by 10 percent in
average. The pool size and secretion rate of apoC-III decrease non-significantly,
respectively going from 11.52 to 10.03 mg/dL and from 7.82 to 7.35 mg/(kg
day).
For apoE the FCR increases significantly, from 0.26 to 0.38 pools/day, the
increase in average amounting to 45 percent. The pool size of apoE decreases
significantly with increase in average of 33 percent. The secretion rate for apoE
decreases only slightly (going from 0.74 to 0.69 mg/( Kg day)).
The information delivered from Figure 5.2 is very valuable. For apoC-III PS
and SR we can notice how the parameters tend mostly to decrease from visit
one to visit two, but the presence of an outlier, the same individual in both cases,
shifts this balance and erase the possibility of a significant decrease for these
two parameters from visit one to visit two. For LDL cholesterol, the massive
decrease is highlighted by reduction of the scatter plot to a very narrow area of
the graph.
Summary of results for evolocumab Few changes between before and after
the evolocumab treatment are strongly significant. First is the decrease in ApoB
(with decrease in average of 53 percent and p<0.001). Secondly, the decrease(in
average) 70 percent of LDL cholesterol (p<0.001). Significant is also a decrease
in cholesterol (decrease in average 41 percent with p<0.001). Other significant
changes are an increase in HDL cholesterol (increase in average 17 percent with
p<0.001). Moreover we can notice a decrease in ApoA1 (in average 7 percent
and p=0.005).
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Figure 5.2: Kinetic parameters and relevant covariates before (x axis) and after (y axis)
evolocumab treatment
Many of the biological parameters are affected by the treatment. ApoE reports
an increase (average 45 percent) of its fractional catabolic rate (p<0.001), while its
pool size diminishes significantly (p=0.001 with decrease in average amounting
33 percent). ApoC-III is affected in its FCR that increases with increase in
average of 10 percent (p=0.03). ApoA4 experiences an increase in FCR and SR,
but these might not be truly reliable due to the scarcity of the apoA4 data, as
noticable in Table 3.2 at page 32.
5.3.3 Liraglutide
General description of results
Individual characteristics After the liraglutide treatment weight decreases
significantly (p<0.001) going from a mean of 100 kg to a mean of 98 kg. The
cholesterol level decreases in a non-significant way, going from 3.86 mmol/L
in average to 3.96 mmol/L. LDL cholesterol level decreases significantly with
a decrease in mean of 12 percent. HDL cholesterol level remains almost un-
varied in mean (1.74 mmol/L at visit one and 1.68 mmol/L at visit two). The
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visit 1 visit 1 visit 2 visit 2 mean
mean std mean std change(%) p-value
Weight 100.29 10.65 98.17 10.6 -2 <0.001
Cholesterol 3.76 0.73 3.56 0.7 -5 0.061
LDL cholesterol 2.01 0.74 1.78 0.64 -12 0.01
HDL cholesterol 1.24 0.34 1.24 0.37 0 0.958
Triglyceride 1.73 0.69 1.65 0.67 -5 0.454
Glucose 9.51 2.33 7.81 1.53 -18 <0.001
Liver fat 15.6 7.57 11.6 6.07 -26 <0.001
Table 5.11: Comparison of relevant individual characteristics before and after the liraglu-
tide treatment. Weight is expressed in Kg, cholesterol, LDL cholesterol, HDL cholesterol,
TG and glucose are in mmol/L, while liver fat is in percentage
triglyceride levels remain stable, their average going from 1.74 mmol/L to 1.53
mmol/L. Glucose level and liver fat level decrease significantly, the first going
from 9.51 mmol/L to 7.81 mmol/L) and the second going from 15.6% to 11.6%
(respectively 18 and 26 percent decrease in mean).
visit 1 visit 1 visit 2 visit 2
mean std mean std change (%) p-value
apoA4 FCR 2.31 0.07 2.99 0.49 29 <0.001
apoA4 PS 15.49 3.71 13.86 2.8 -11 0.166
apoA4 SR 1.91 0.46 2.19 0.42 14 0.1
apoC-III FCR 1.5 0.15 1.91 0.43 27 0.002
apoC-III PS 11.55 4.48 9.84 3.88 -15 0.066
apoC-III SR 8.98 3.03 9.4 2.96 5 0.624
apoE FCR 5.73 0.42 5.72 0.88 0 0.963
apoE PS 5.93 1.21 4.91 1.03 -17 0.01
apoE SR 1.79 0.26 1.47 0.2 -18 <0.001
Table 5.12: Comparison of kinetic parameters before and after the liraglutide treatment.
FCRs are expressed in pools/day, PS is expressed in mg/dL and SR in mg/( Kg day)
Kinetic parameters Two of the kinetic parameters for apoA4 (FCR and SR)
have undergone a seemingly relevant change between before and after the
treatment (respectively increasing in mean by 29 and 14 percent), only the first
one being significant, while the second being above the significance level (0.1).
The pool size have decreased by 11 percent in mean, this decrease not being
significant. As already mentioned for the fructose and evolocumab treatment,
apoA4 parameter estimates might not be so reliable as the estimates for apoC-III
or apoE.
The FCR of apoC-III has increased considerably (with increase in average of 27
percent) and significantly. The pool size has undergone a decrease in mean of
15 percent, this being slightly above the significance level. The SR of apoC-III
have increased in average by 5 percent, but this increase is not significant.
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Figure 5.3: Kinetic parameters and relevant covariates before (x axis) and after (y axis)
liraglutide treatment
For apoE, while the FCR remains almost unvaried, the pool size and the SR
decrease significantly (respectively with a decrease in average of 17 and 18
percent).
Other than confirming the results for the significant and non-significant changes
between the two visits, an incongruence of range is to be noticed for the FCR of
apoA4 in Figure 5.3.
The range for the FCR of apoA4 is very narrow for the first visit and the values
are very low, while they become much higher in the second visit, with the range
being larger.
This incongruity could be ascribed to the poor quality of the data, as seen in
Table 3.3 at page 33.
Summary of results for liraglutide Few of the individual characteristics have
decreased significantly between before and after the liraglutide treatment. LDL
cholesterol, glucose and liver fat levels have undergone significant and substan-
tial decreases (respectively 12, 18 and 26 percent decrease). The slight decrease
in body weight is significant, with average decrease of 2 percent.
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The liraglutide treatment has also brought significant changes in some of the
kinetic parameters. We notice significant changes in all the three apolipopro-
teins; we focus on the changes in apoC-III and apoE due to the low quality of
the apoA4 data. The FCR of apoC-III undergoes an increase in average of 27
percent, while the decrease in pool size (15 percent in average) is slightly above
the significance level (p=0.066). Pool size and SR for apoE decrease respectively
by 17 and 18 percent, both of the changes being significant.
5.4 Correlation of kinetic parameters with selected
covariates
As a result of the treatments, significant changes occur in some of the kinetic
parameters of the three apolipoproteins under analysis and the individual char-
acteristics.
We would like to investigate whether existing baseline correlations between
an individual characteristic and the kinetic parameter are maintained with the
intervention or whether new ones arise (Picture 1) and whether the changes in
these two variables between the first and second visit correlate (Picture 2).
5.4.1 Fructose
HDL cholesterol
Figure 5.4 (Picture 1):
HDL cholesterol correlates at visit one with apoA4 PS, but this relationship is
not kept at the second visit. Slightly above the significance level is the p-value
for the linear relationship between FCR of apoE and the HDL cholesterol at visit
one.
Figure 5.5 (Picture 2):
There are no significant correlations between the changes in HDL-cholesterol
and the changes in the kinetic parameters.
Conclusions
No strong correlations can be found between HDL cholesterol levels and the
kinetic parameters, nor between their changes.
LDL cholesterol
Figure 5.6 (Picture 1):
Several of the regression lines describing the kinetic parameters as a linear
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Figure 5.4: Individual HDL cholesterol levels (x axis) and kinetic parameters (y axis)
before (green) and after (red) fructose treatment
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Figure 5.5: Individual changes in HDL cholesterol levels (x axis) and kinetic parameters
(y axis) between before and after fructose treatment
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Figure 5.6: Individual LDL cholesterol levels (x axis) and kinetic parameters (y axis)
before (green) and after (red) fructose treatment
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Figure 5.7: Individual changes in LDL cholesterol levels (x axis) and kinetic parameters
(y axis) and kinetic parameters between before and after fructose treatment
function of the LDL cholesterol have statistical significance. At visit one the
correlation between LDL cholesterol and apoC-III FCR is significant. For both of
the visits, the correlation between LDL cholesterol and the pool size of apoC-III
and the SR of apoC-III is significant.
Regarding apoE, a significant correlation with apoE FCR is present at visit two,
while a correlation with the pool size of apoE is present at visit one.
Figure 5.7 (Picture 2):
The picture fails to highlight any significant correlations between the changes
in LDL-cholesterol and the changes in the kinetic parameters.
Conclusions
LDL cholesterol strongly correlates with apoC-III FCR and apoC-III PS at visit
one. The relationships respectively loses its significance and become weaker at
visit two.
There is no significant correlation between changes in LDL cholesterol and the
ones in the kinetic parameters.
Triglyceride levels
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Figure 5.8: Individual triglyceride levels (x axis) and kinetic parameters (y axis) before
(green) and after (red) fructose treatment
Figure 5.8 (Picture 1):
The p-value for the hypothesis test on the slope in the linear relationship be-
tween the triglyceride levels and the FCR of apoA4 is slightly above the signifi-
cant level at visit one. The correlation between apoC-III FCR and the triglyceride
levels at visit one is significant. The relationship between the pool size and
the SR of apoC-III and the triglyceride levels deserves special attention. The
correlation between them is significant and the relationship does not change
significantly between the two visits. In fact we see that the green point move
to the red point parallel to the regression line, implying that the relationship
remains unvaried between the two visits.
For apoE each of the parameters have a significant correlation with the triglyc-
eride levels, for only one of the two visits, the FCR at visit two (visit one only
being slightly above the significance level), PS at visit one (visit two having
p-value of 0.07) and SR at visit one.
Figure 5.9 (Picture 2):
For apoC-III pool size and SR, their changes correlate significantly with the
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Figure 5.9: Individual changes in triglyceride levels (x axis) and kinetic parameters (y
axis) between before and after fructose treatment
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Figure 5.10: Individual HDL cholesterol levels (x axis) and kinetic parameters (y axis)
before (green) and after (red) evolocumab treatment
change in triglyceride levels. For the SR of apoC-III, the p-value of the hy-
pothesis test on the intercept being 0 is 0.44, therefore we can imply a merely
proportional relationship between the changes in apoC-III pool size and the
triglyceride levels.
For apoE the change in FCR can be described linearly as a function of the change
in triglyceride levels.
Conclusions
ApoC-III PS and SR correlate strongly with the triglyceride levels at visit one
and at visit two, keeping an almost unvaried linear relationship. The changes
of the kinetic parameters and of triglyceride levels correlate too.
Additionally triglyceride levels correlate positively with apoE PS at visit one.
At visit two they correlate negatively with apoE FCR.
5.4.2 Evolocumab
HDL cholesterol
Figure 5.10 (Picture 1):
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Figure 5.11: Individual changes in HDL cholesterol levels (x axis) and kinetic parameters
(y axis) between before and after evolocumab treatment
Only the correlation between apoC-III secretion rate and HDL cholesterol is
significant at visit one, while the other kinetic parameters show non significant
relationship to HDL cholesterol.
Figure 5.11(Picture 2):
From the picture, we can see that there are no significant correlations between
the changes in HDL cholesterol and the changes in the kinetic parameters.
Conclusions
HDL cholesterol levels at visits one or two do not show any strong correlation
with the kinetic parameters, nor such associations exist among the changes of
these quantities.
LDL cholesterol
Figure 5.12 (Picture 1):
Slightly above the significance value is the p-value for the correlation between
the LDL cholesterol and the FCRs of apoA4, apoC-III and apoE, the first ones at
visit one and the latter at visit two.
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Figure 5.12: Individual LDL cholesterol levels (x axis) and kinetic parameters (y axis)
before (green) and after (red) evolocumab treatment
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Figure 5.13: Individual changes in LDL cholesterol levels (x axis) and kinetic parameters
(y axis) between before and after evolocumab treatment
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Figure 5.14: Individual triglyceride levels (x axis) and kinetic parameters (y axis) before
(green) and after (red) evolocumab treatment
Figure 5.13 (Picture 2):
The picture fails to show any significant correlations between the changes in
LDL-cholesterol and the changes in the kinetic parameters.
Conclusions
LDL cholesterol does not show significant correlations with the kinetic parame-
ters for the apolipoproteins and such relation is non-existent also between the
changes in these variables.
Triglyceride levels
Figure 5.14 (Picture 1):
The p-value for the correlation of apoA4 PS with triglyceride is slightly above
the significance value at visit one. Significant is the correlation between the SR
for apoA4 and the triglyceride level.
The significant linear relationship between the pool size and the secretion rate
of apoC-III and the triglyceride levels are worth noticing. Both of them are
significant at both of the visits. The points move parallel to the green line,
resulting in the red lineoverlapping with the green line, for the apoC-III PS and
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Figure 5.15: Individual changes in triglyceride levels (x axis) and kinetic parameters (y
axis) between before and after evolocumab treatment
almost overlapping for the apoC-III SR.
For apoE, the PS and secretion rate can be described linearly as a function of
the triglyceride only for the second visit.
Figure 5.15 (Picture 2):
The change in pool size for apoA4 can be described linearly as a function of the
change in triglyceride levels.
Significant is also the linear relationship between the changes in PS and SR for
apoE and apoC-III and the triglyceride levels.
Conclusions
Triglyceride levels correlate strongly with apoC-III PS and SR at both visits,
keeping an almost unvaried linear relationship. The changes in triglyceride lev-
els and in these two kinetic parameters also correlate. At visit two, triglyceride
levels correlate with apoE PS and SR.
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Figure 5.16: Individual HDL cholesterol levels (x axis) and kinetic parameters (y axis)
before (green) and after (red) liraglutide treatment
5.4.3 Liraglutide
HDL cholesterol
Figure 5.16 (Picture 1):
The PS and SR of apoE are the only ones who have a significant linear relation-
ship with the HDL cholesterol level and this holds only for the first visit.
Figure 5.17 (Picture 2):
None of the correlations between changes in HDL cholesterol and the kinetic
parameters are significant.
Conclusions
No strong correlation can be noticed between HDL cholesterol and the kinetic
parameters, nor between the changes in HDL cholesterol and the changes in the
apolipoprotein kinetic parameters.
LDL cholesterol
Figure 5.18 (Picture 1):
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Figure 5.17: Individual changes in HDL cholesterol levels (x axis) and kinetic parameters
(y axis) between before and after liraglutide treatment
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Figure 5.18: Individual LDL cholesterol levels (x axis) and kinetic parameters (y axis)
before (green) and after (red) liraglutide treatment
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Figure 5.19: Individual changes in LDL cholesterol levels (x axis) and kinetic parameters
(y axis) between before and after liraglutide treatment
Slightly above the significance level is the p-value for the correlation between
apoA4 SR and LDL cholesterol level.
Figure 5.19 (Picture 2):
There is no significant correlation of the changes in kinetic parameters with
changes in the LDL cholesterol level. It can be noticed, though, that the p-value
for the linear relationship between SR of apoE and LDL cholesterol level is very
close to the significance level (0.073).
Conclusions
There are no significant correlations between LDL cholesterol and the kinetic
parameters at visit one nor at visit two, nor between the changes among visit
one and two.
Triglyceride levels
Figure 5.20(Picture 1):
The FCR for apoC-III at visit two correlate with the triglyceride levels (p=0.049).
At visit one the p-value is not so far from the significance value (p.value 0.085).
The pool size of apoC-III correlates with the triglyceride levels in both of the
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Figure 5.20: Individual triglyceride levels (x axis) and kinetic parameters (y axis) before
(green) and after (red) liraglutide treatment
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Figure 5.21: Individual changes in triglyceride levels (x axis) and kinetic parameters (y
axis) between before and after liraglutide treatment
visits, while its SR correlates with this covariate only at visit one.
Significant are the correlations of apoE PS and apoE SR with the triglyceride
levels, but only at visit 1.
Figure 5.21(Picture 2):
The only significant correlation is the one between the changes in SR of apoE
and in the triglyceride levels.
Conclusions
The triglyceride levels correlate with the PS and SR of apoC-III but this relation-
ship respectively becomes weaker and loses its significance at visit two.
5.4.4 General conclusions
In the fructose experiment, LDL cholesterol correlates strongly with apoC-III
FCR and PS only at visit one. Triglyceride levels correlate at visit one with
apoC-III PS and SR, consistently for all the apolipoproteins. In the fructose
5.4. Correlation of kinetic parameters with selected covariates 103
and evolocumab experiments these correlations are also kept at the second
visit, with an almost unvaried linear relationship among these quantities and
the changes in these variables between the visits correlate with the changes in
triglyceride levels. This highlights a tight bond between triglyceride, apoC-III
PS and SR.
In the fructose and evolocumab experiments, associations could be found at
some of the visits between triglyceride levels and kinetic parameters of the
apolipoproteins, but these are not consistent across the studies.
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6 Summary of papers
6.1 Paper I and Paper II
Increased fasting and postprandial triglyceride concentration after hypercaloric
fructose treatment had been observed in systematic reviews and meta-analysis
[70, 71, 72], but so far it was not elucidated how.
Though apoC-III is known to be an inhibitor of TRL kinetics, a kinetic study of
apoC-III in a hypercaloric fructose intake setting had not been performed yet.
This is to our knowledge the first example of such a study.
Datasets for apolipoproteins A-4, C-III and E were created from blood samples
through a spectrometry-based proteonomics technology. In Paper I a newly-
developed modelling framework is applied to the kinetic study of the three
apolipoproteins and the results are reported. Due to the combined analysis,
correlation structure of the different apolipoproteins with each other can be
analysed. ApoC-III and apoE fractional catabolic rates correlate at baseline
as well as the pool sizes of the two apolipoproteins. ApoC-III and apoE are
related at baseline with triglyceride levels and for apoC-III the relation with
triglyceride holds also after the treatment. ApoC-III concentration increases
due to an increased secretion rate.
In Paper II the results for apolipoprotein C-III for 11 individuals are com-
bined with the results of non-steady state kinetics of apoB48- and of apoB100-
containing lipoproteins.
As a result of the Fructose hypercaloric treatment many indicators change as
shown in Figure 6.1.
ApoC-III increases in concentration (+31.3%, p=0.002) largely due to an in-
creased secretion rate (+30.4%, p=0.01).
The changes in apoC-III concentration correlate with changes in VLDL1 triglyc-
eride (r = 0.75) and in VLDL-apoB100 (r=0.68) and plasma triglyceride (r = 0.79)
as it can be seen in Figure 6.2.
In fact, the increased plasma triglycerides was caused by delayed lipolysis as
measured by the decreased VLDL1 to VLDL2 fractional transfer rate. In con-
trast, VLDL1 triglyceride secretion was not increased by fructose intervention.
We can conclude that fructose intervention induced an increased secretion of
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Figure 6.1: Boxplots for the changes in relevant individual characteristics and kinetics
parameters
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Figure 6.2: Linear regression among changes in individual characteristics and changes
in apoC-III PS (A-C) and SR (D)
apoC-III resulting in increased apoC-III concentration and delayed lipolysis of
plasma triglycerides.
6.2 Paper III
PCSK-9 fosters the degradation of LDL receptors. PSCK-9-inhibitor based drugs
therefore increase LDL-receptor availability. Dyslipidemia is a common char-
acteristic among type-II-diabetic patients. One of its hallmark is the increased
LDL concentration.
Apolipoprotein E (apoE) is a binder for LDL receptor and apolipoprotein C-III
(apoC-III) is an inhibitor of lipoprotein lipase, especially active in the VLDL1
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Figure 6.3: Boxplots for the changes in the individual characteristics and relevant kinetic
parameters. One star indicates a pvalue smaller than 0.05 while two stars indicate a
pvalue smaller than 0.01
fraction [73].
This study analyses apoC-III and apoE postprandial kinetics before and after
evolocumab treatment on the background of statin therapy.
The data generated with proteomic technology are analysed with nonlinear
mixed effects models approach. The model developed in Paper I was used to
analyse apoE and apoC-III kinetics separately.
The treatment has led to an improvement of the lipid profile and to changes in
many kinetic parameters as can be seen in Figure 6.3. ApoE concentration is
significantly reduced (-33% with p=0.001), largely due to an increased fractional
catabolic rate for apoE (45% increase with p<0.001). The correlation structure
of the individual characteristics and the apolipoprotein kinetics parameters
together with considerations about the contribution of the different lipoprotein
fractions to the apolipoprotein E FCR hint to the fact that the observable effects
on the fasting lipoprotein concentrations and on apoE might be largely due to
an increased VLDL2 FCR. Only the combination of our results with lipoprotein
kinetics study can confirm or disprove this hypothesis.
7 Conclusions and future work
7.1 Contributions to the field
Apolipoproteins are key-role players in metabolic diseases.
Despite advances in computational tools in general, implementation of these
has been slow in many fields. Data in this thesis is generated with a novel,
semi-automatic, low-cost proteomics based method. When combined, these
instruments allow us to rapidly determine plasma kinetics of apolipoproteins.
The key ingredient with which the software shall be fed is the structural model
and several small choices shall be done on the statistical model. Here re-
sides the contribution of the author to the research field. For the first time
a full framework for apolipoprotein modelling (comprehensive of structural
model and statistical model) has been developed and validated for the study
of the three apolipoproteins: apoA4, apoC-III and apoE. This systematic ap-
proach, illustrated in the box, could be applied in the future to other studies of
apolipoprotein kinetics. The kinetic data for apolipoproteins A4, C-III and E
have been analysed for the first time before and after a fructose treatment and a
evolocumab treatment.
Kinetic studies combined with mathematical modelling help us make inference
on biological processes. In this work, the field of application was the study of
dyslipidemia in type II diabetic individuals and abdominally obese individuals.
Due to the analysis through mathematical modelling, advances in the knowl-
edge in the biological domain have been unlocked. Even though all the studies
reported significant changes in some parameters for apoA4 kinetics, the quality
of data was worse for apoA4, therefore we have chosen to mostly focus on the
results regarding the apoE and apoC-III kinetics in the papers.
In Paper I we present the developed modelling framework and we apply it to
the kinetic study of apolipoproteins A4, C-III and E before and after a fructose
treatment. Paper II highlights that increased secretion of apoC-III causes the
increase in triglyceride levels, by reducing the fractional transfer rate of VLDL1
particles to VLDL2. Thus, further knowledge can be gained when we combine
our results with other results from the same individuals.
In Paper III evolocumab, PCSK9-inhibitor based drug have been shown to
decrease the level of apoE concentration in the blood, by increasing apoE FCR.
ApoC-III FCR is also increased to a smaller extent.
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Model equations
Transversal through the different apolipoproteins, as shown in pages 39- 40 with
measurement function as in page 41
Standard statistical model
• distribution of the random effects: log-normal
• error model: remove parameters with relative standard error (rse) > 100
• variance covariance matrix : to the diagonal matrix add a correlation group
for the random effects of the parameters p1, Q1 and k01
Procedure
• Do the analysis with different statistical models (GEM, DDEM, GEM + COV,
DDEM + COV) as explained in Section 4.4
• Do all the models provide good individual fits? In this case proceed with
the following step.
• Do all the models provide plausible ranges for the values of the biological
parameters? Proceed with the following step.
• Compare the Akaike criterion for the different models. If DDEM + COV
model delivers the best Akaike criterion (or if it is only slightly worse than
others) and all the parameters show log-normality, eventually after removing
an outlier, choose this model. If it is much worse for the DDEM + COV
model or if the test for normality does not hold even after removing an
outlier, go through the following procedure. At every step, before checking
the Akaike criterion, make sure that the new estimation provides good fit to
the individual curves and the ranges for the parameters are not too narrow.
– check whether one parameter for the error model with RSE not far
from 100 was eliminated. Reinsert it while keeping the covariance
matrix COV (this will become the DDEM2+COV) and check the Akaike
criterion again. If no superfluous removal had been performed in the
error model choice, the DDEM is the new terms of comparison, therefore
the Akaike criterion for the new tested models shall have the AIC for
the DDEM as a comparison term. If the AIC was not improved inthis
step and/or a parameter show log-normality even after an eventual
removal of an outlier, proceed with the following step in parallel with
the DDEM+COV and DDEM2+COV
– Simplify the correlation structure by removing the included correlation
couple in the variance covariance matrix with highest p-value. If Akaike
criterion is better than for the DDEM (or DDEM2) model or if it just
slightly worse, choose this model (DDEM or DDEM2) with simplified
variance-covariance matrix, otherwise perform another calculation with
DDEM2 model (if necessary) (without the minimal variance-covariance
matrix) and compare the obtained Akaike criterion with the AIC for
the different models. Choose the model that has substantially better
AIC and the normality holds for all the parameters (eventually after
removing an outlier).
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While the application of mathematics to problems in biology has a huge poten-
tial in advancing understanding of the human body, the combination of the two
fields sometimes penalizes mathematical modelling. In fact the target audience
of the message is the biological community, so even though mathematics is
essential to obtain the results on the biology, most of the time it is not sensational
enough to deserve a detailed description of the model in the methods section
of the paper. Therefore choices like the distribution of the random effects or
the choices on the error model are most of the time not cited and the equations
are not presented. This makes it hard to evaluate what the novelty of the work
of the modeller, since similar choices might have been made before from other
researchers but not been reported explicitly in papers.
Another aspect that needs improvement is the communication in the collabora-
tive setting between the medical doctors or biologists with the mathematicians.
A deep discussion shall be opened at the onset of the research questions so
that the experimental design to investigate them will generate an informative
dataset. The risk with not complying with this practice is that huge amounts of
resources might be wasted if conclusions cannot be drawn due to a poor quality
of data.
Another important point is that data shall be shared, so that it can be further
analysed for other research purposes. This would be very important also for an
educational purpose. The wider availability of real-world data could make the
discipline of biomathematics more appealing for younger students.
7.3 Future work
Peptides are sequences of amino acids which are part of a protein. In the spec-
trometry analysis, more than one peptide specific to each apolipoprotein have
been singled out and measured; each of them representing a signal for the
concentration of the protein. In this work, we have selected for each apolipopro-
tein the peptide with the most abundant number of time points. One possible
extension for future work is to consider the whole set of peptides for each
apolipoprotein. The combination of different signals could potentially lead to
more robust estimates.
In this work, we have analysed separately the data for the two visits and then
compared them. One could alternatively think about the discrepancy between
the parameters at the two visits as a fixed effect and integrate it into the statisti-
cal model. In this case, one could analyse the data for the same apolipoprotein
for the two visits together. In order for the response from this comprehensive
model to be informative (showing which parameters have truly been affected)
and not represent only a computational burden, one shall accurately choose
which parameters shall contain the fixed effect.
In this work, three datasets were analysed, one regarding abdominally-obese
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individuals and the remaining two comprehending individuals with type-II-
diabetes. One possible continuation of this work would be to compare the
kinetic parameters for the apolipoproteins across the different groups. One
could check whether the parameters are consistent across the two diabetic
groups and whether differences exist between these and the abdominally obese
group. This requires refinement of the data, for example through weight and
gender matching, so that the results of the comparison can truly be informative.
Major players in lipid metabolism, apolipoprotein action can only be fully un-
derstood when connected to lipoprotein analysis, the particles where they are
attached. In Paper II, the results of the apolipoprotein kinetic data analysis, from
the author, are combined with the results of the lipoprotein analysis. The dots
are connected in this way and a comprehensive understanding of the treatment
effect can be drawn.
The integration of the results in Paper III with the ones about lipoprotein kinet-
ics is required to access to the full potential of the study.
In the integrative analysis in Paper II the results are combined after the param-
eters have been estimated separately with two different models (one for the
apolipoprotein and one for the lipoproteins), but one can envision having a
unique model that combines apolipoprotein kinetics and lipoprotein kinetics. If
this combined model would be practicable, some quantities could potentially be
used as covariate and with the same cost for the experiment more individuals
could be analysed.
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Appendix
Chemical analysis for the fructose intervention
Study design
Postprandial kinetic study After an overnight fast, subjects were admitted
and a baseline blood sample were drawn at approximately 7:30 am. A bolus
injection of [5,5,5-2H3]-leucine (7 mg/kg) was given at 8:00 am. At 10:00 am,
the subjects received a fat-rich meal served with a cocoa-fat rich emulsion
containing 40 g of olive oil (Amway, Firenze). The meal consisted of bread,
cheese, ham, boiled eggs, fresh red pepper, low-fat (1%) milk, orange juice and
tea or coffee. Altogether the meal contained 63 g carbohydrate, 69 g fat and 40
g protein, and was consumed within 10 min. The subjects remained physically
inactive during the study but were allowed water ad libitum. Blood was drawn
between 8:00 am and 6:00 pm as described in [49].
Intra-abdominal fat depots Liver fat content was measured using proton
magnetic resonance spectroscopy [75, 76] and subcutaneous abdominal and
intra-abdominal fat were measured using magnetic resonance imaging [74] as
previously described.
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Measurement of apoC-III, apoE and apoA4 enrichments
Internal standard peptides Stable-isotope-labeled SpikeTides TQL peptides
for apoC-III (DALSSVQESQVAQQAR), apoE (LQAEAFQAR) and apoA4 (IDQN-
VEELK), were purchased from JPT Peptide Technologies (Berlin, Germany).
The stable isotope labels (13C615N4 for Arg, 13C615N2 for Lys) were at the C-
terminal Arg and Lys residues and a trypsin-cleavable quantification tag (QTag).
Purity for each peptide was >95%. The stable-isotope-labeled peptides were
used as internal standards (ISTDs) for absolute quantification of apoC-III, apoE
and apoA4 respectively. The peptides (1 nmol) were dissolved and diluted in
1% sodium deoxycholate in 100 mmol/l triethylammonium bicarbonate (TEAB)
to an ISTD master mix at concentrations of 100 fmol/µl (apoC-III), 15 fmol/ µ
L (apoE) and 24 fmol/µL (apoA4). Initially calibration curves were prepared,
in which the linearity of the mass spectrometric (MS) determination of the
peptides was verified with the internal standard (ISTD) peptides spiked into
representative pooled plasma samples. A total of seven plasma digests were
prepared as described below with an equimolar mixture of the apoC-III peptide.
The concentration interval for peptides was 7 to 469 fmol. This corresponds
to a concentration in the plasma of 15 to 938 fmol/µL. For apoE and apoA4
concentration for peptides ranged from 5 to 234 fmol, corresponding to a plasma
concentration of 11 to 469 fmol/µL. The MS response was found to be linear
within this concentration range for all peptides.
Tryptic digestion of plasma Plasma samples from blood samples drawn be-
fore and during the fat-rich mixed meal test were thawed at room temperature
and vortexed for 10 min. Plasma (10 µl) was diluted in 340 µl 100 mmol/l TEAB,
and 15 µl of diluted plasma was mixed with 10 µl 5% sodium deoxycholate
and 3 µl 50 mmol/l DL-dithiothreitol (DTT, Sigma-Aldrich). The samples were
reduced for 20 min at 60oC and then alkylated with 1.5 µl 200 mmol/l S-Methyl
methanethiosulfonate (MMTS, Sigma-Aldrich) for 20 min at room temperature.
The reaction mixture was then diluted in 10 µl 100 mmol/l TEAB and 15 µl ISTD
master mix was added. This mixture was digested overnight with 10 µl (0.06
mg/ml) trypsin (Pierce) at 37oC. A second aliquot of 10 µl trypsin (0.06 mg/ml)
was added and digestion continued for 3 h at 37oC. H2O (10 µl) and 20 µl 10%
trifluoroacetic acid was added to stop digestion and precipitate sodium deoxy-
cholate. Samples were centrifuged for 15 min at 3700 rpm, and the supernatants
were desalted on a SOLAµ HRP 96-well plate (Thermo Fisher, USA) using a
positive pressure manifold (Biotage) and lyophilized to dryness. For Liquid
Chromatography Mass Spectrometry (LC-MS) analysis, the samples were re-
suspended in 15 µl solution containing 3% acetonitrile and 3% formic acid. The
final samples for injection contained the labelled peptides at a concentration of
100 fmol/µl for apoC-III, 15 fmol/µL for apoE and 23.3 fmol/µL for apoA4.
Parallel reaction monitoring (PRM) for absolute quantitation The PRM anal-
yses were performed using a Q-Exactive mass spectrometer interfaced to an
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Easy-nLC 1200 (Thermo Fisher, USA). The LC conditions for separation and MS
parameters were optimized to enhance the detection of the fragment ions con-
taining d3-leucine. Peptides were trapped on an Acclaim Pepmap 100 C18 trap
column (100 µm x 2 cm, particle size 5 µm, Thermo Fisher, USA) and separated
on an in-house packed analytical column (150 x 0.075 mm I.D) packed with 3 µm
Reprosil-Pur C18-AQ particles (Dr. Maisch, Germany) using a linear gradient
of buffers A and B, from 10% to 35% B over 12 min followed by an increase to
100% B for 8 min and a washing step at a flow of 300 nl/min. Solvent A was
0.2% formic acid in water and solvent B was 80% acetonitrile in 0.2% formic
acid. Ions were injected into the mass spectrometer under a spray voltage of 1.8
kV in positive ion mode. For the PRM method, an orbitrap resolution of 35 000
(at m/z 200), a target automatic gain control value of 5e6, a maximum fill time
of 80 ms, and a quadrupole isolation window of 2 Th were used. The precursor
ions of the endogenous, the D3endogenous and labeled peptides were targeted
at their 2+ charge state, triggered by a scheduled inclusion list. Fragmentation
was performed with normalized collision energy (NCE) of 27. Raw mass spec-
trometry data (Thermo Fisher, USA) were exported to Skyline (version 3.x.x)
for extraction of the fragment ions and peak area integration. The integration
boundaries were manually verified for all peaks in the samples. A list of the
precursor ions for the corresponding pairs of endogenous, d3-endogenous and
labelled peptides and selected fragment ions is given in Table 1. All the ion
fragments used for determine turnover and the ratio of endogenous and d3-
endogenous contained d3-leucine. To determine the linearity of the peptides
in the standard curve samples, a regression analysis was performed on the
individual fragments from the peptides. The ISTD peptides were spiked in the
individual plasma samples at concentrations close to 1:1 to those determined
for their endogenous counterparts in the pool of samples analyzed in the stan-
dard curve. The concentration of the endogenous peptides in the individual
study samples were calculated from the concentration of the labelled peptide
(100, 15 and 23.3 fmol/µl for apoC-III, apoE and apoA4 respectively, quan-
tification based on single point measurement concept) the Ratio-To-Standard
(endogenous/labelled peptide) x Concentration labelled peptide was used. The
concentrations measured for the endogenous peptides were converted into the
actual concentration of the corresponding proteins in the initial blood samples.
Biochemical analysis Triglyceride and cholesterol concentrations in total
plasma and lipoprotein fractions as well as in triglyceride-rich lipoprotein
(TRL) cholesterol and remnant-lipoprotein (RLP) cholesterol were analyzed us-
ing assays (Denka Seiken, Tokyo, Japan) and the Konelab 60i analyzer (Thermo
Fisher, USA). RLP-C captures lipoproteins not binding with anti-apoA-I and
anti-apoB-100 as remnant lipoproteins [5]. The TRL-C quantifies cholesterol in
both chylomicron remnants, and VLDL-IDL. Fasting and postprandial apoB48
levels in total plasma were measured by ELISA (Shibayagi, Shibukawa, Japan).
Concentrations of plasma glucose and insulin were measured with hexokinase
method (Roche Diagnostic Gluco-quant, Germany) and electrochemilumines-
cence (Roche sandwich immunoassay on a Cobas autoanalyzer), respectively.
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Plasma levels of apoC-III were measured immunoturbidometrically (Kamiya
Biomedical Company, Seattle, WA) and β-hydroxybutyrate concentrations were
measured by an enzymatic method with β-hydroxybutyrate FS kit (DiaSys
Diagnostic Systems, Holzheim, Germany) on a Konelab 60i analyzer.
